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1. Introduction 
 
The discovery of small-molecule inhibitors targeting different post-translational 
modifications has been a hot topic since the last decade. In general, post-translational 
modifications are important events that signal the fate of myriad proteins in the cell. Here, 
we have focused on a specialized post-translational modification, i.e. ubiquitination of 
proliferating cell nuclear antigen (PCNA), where 76-amino-acid residue ubiquitin gets 
covalently attached to PCNA, which recruits translesion DNA synthesis (TLS) 
polymerases which are inherently error-prone and lead to mutagenesis and 
carcinogenesis. Our project is focussed on the discovery of small-molecule inhibitors of 
PCNA ubiquitination so that TLS inhibition can become a part of cancer treatment. The 
small-molecule inhibitors of PCNA ubiquitination could synergize with other anti-cancer 
treatments and reverse drug tolerance in patients who are refractile to present treatments. 
Upon DNA damage, lesions can be left unrepaired from classical DNA repair mechanisms 
and these damages can stall the replication fork during the S-phase of the cell cycle. Here, 
the specialized translesion DNA polymerases come into the play which are specialized to 
bypass these lesions, a process known as translesion DNA synthesis (TLS). Further, TLS 
gets activated by the monoubiquitination of PCNA at the stalled replication fork which 
involves Uba1 (UBE1) as E1 ubiquitin-activating enzyme, Rad6 as a ubiquitin-
conjugation enzyme complex with Rad18 as E3 ubiquitin ligase and PCNA which is the 
ultimate substrate of ubiquitination.   
There can be different ways of targeting error-prone translesion DNA synthesis either by 
inhibition of activity of an individual protein involved in PCNA ubiquitination, by direct 
binding, disruption of a specific regulatory domain/function and/or by blocking regulatory 
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protein-protein interactions. In order to target TLS we have developed a high throughput 
step-specific screening assay to discover small-molecule inhibitors of PCNA 
ubiquitination, ultimately epigallocatechin gallate (EGCG) an inhibitor of PCNA 
ubiquitination targeting Uba1 protein in the ubiquitination cascade was discovered. 
1.1. DNA replication 
All living organisms store information about growth and functioning in the form of DNA. 
DNA replication is an essential, highly organized, strictly controlled and evolutionarily 
conserved process, carried out by complex machinery, involving a myriad of proteins and 
enzymes working together to form a large complex, the replisome.  
The replication of the genome requires DNA unwinding by a special class of proteins 
called helicases. The replicative helicases are multi-subunit protein complexes. The 
eukaryotic replicative helicase is composed of 11 subunits, requiring an assembly of two 
subcomplexes and one protein. The hetero-hexameric MCM2-7 helicase is activated by 
forming a complex with Cdc45 and the hetero-tetrameric go-ichi-ni-san (GINS) complex 
forming a Cdc45-Mcm2-7-GINS (CMG) complex (Figure 1), the replicative helicase 
complex (Boehm, Gildenberg, and Washington 2016). After unwinding, the single-
stranded DNA becomes unstable and can be exposed to endonucleases. Human 
replication protein A (RPA) stabilizes the single-stranded DNA by binding to it (Wold 
1997; Wobbe et al. 1987). The synthesis of DNA requires an RNA primer, the synthesis 
of which is catalyzed by primase and DNA polymerase α (Pol α). The Pol α-primase 
complex is required by the processive classic polymerases for bulk DNA synthesis 
(Pellegrini 2012). The RNA primer attaches itself to the template strand, replication factor 
C (RFC) binds to the primer-template junction and catalyzes the loading of PCNA, which 
encircles DNA. PCNA will recruit DNA polymerases such as polymerase alpha, delta and 
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epsilon (L. M. Johnson et al. 1985). DNA polymerases move continuously in one 
direction on the leading strand and discontinuously on the lagging strand by the formation 
of short fragments known as Okazaki fragment, Okazaki fragments are short sequences 
of DNA nucleotides (approximately 150 to 200 base pairs long in eukaryotes) which are 
synthesized discontinuously and later linked together by the enzyme DNA ligase to create 
the lagging strand during DNA replication (Figure 1) (Sugimoto, Okazaki, and Okazaki 
1968; Sugimoto et al. 1969; Okazaki and Okazaki 1969). During the replication of 
Okazaki fragments, thousands of nicks are formed that undergo efficient processing by 
the coordination between DNA polymerase δ and FLAP endonuclease (FEN1). When the 
replicative polymerase reaches the end of the DNA synthesis on the Okazaki fragment, it 
partially displaces this fragment by the ongoing DNA synthesis and a flap structure is 
formed through the activity of flap structure-related endonuclease (FEN1); this structure 
is cut out and the resulting nick is sealed by DNA ligase I. The coordination of 
polymerases and FEN1 is more efficient in polymerase δ than other polymerases (Garg et 
al. 2004). PCNA elevates the efficiency of the DNA replicative polymerase, which 
replicates the bulk of the DNA (Moldovan, Pfander, and Jentsch 2007). 
                               
Figure 1. Schematic representation of the eukaryotic replication fork. The red bars 
represent the Okazaki fragments on the lagging strand. The Polε replicating at leading 
strand and Polδ is replicating the lagging strand template. The CMG complex, a 
replicative helicase complex (R. E. Johnson et al. 2015).  
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1.2. DNA damage 
Genomic DNA is consistently exposed to various endogenous and exogenous damaging 
agents (Mazouzi, Velimezi, and Loizou 2014; Lindahl and Barnes 2000). Endogenous 
DNA damaging factors are the products of cellular metabolism such as reactive oxygen 
species (ROS), lipid peroxidation, propano adducts, ethano adducts and malondialdehyde 
induced damage, etc (De Bont and van Larebeke 2004). Exogenous sources or direct-
acting agents are ultraviolet radiations, ionizing radiations, nitrogen mustard, 
formaldehyde, nitrosamines, etc. (Jena 2012). If damaged DNA remains unrepaired, it 
can lead to mutagenesis and thus carcinogenesis (Figure 2) (Negrini, Gorgoulis, and 
Halazonetis 2010; Shen 2011). 
                                
Figure 2. DNA damage response. Endogenous and exogenous sources causing DNA 
damage trigger DNA damage response (DDR), which consists of an intricate network 
between cell cycle checkpoint control, DNA repair and transcriptional regulation or, in 
case of excessive DNA damage, programmed cell death mechanisms. 
1.3. DNA damage tolerance/bypass 
Cells have an amazing system to handle assault to DNA, the so-called DNA damage 
response network. DNA damage is caused by different factors and the degree of damage 
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can vary, thus,  different repair mechanisms have evolved to heal the damaged regions 
(Friedberg 2005). These mechanisms include direct reversal by photolyase (Sancar 1996), 
homologous recombination (HR) (Helleday et al. 2007), non-homologous end joining 
(NHEJ) (Weterings and Van Gent 2004), nucleotide excision repair (NER) (Sancar 1996; 
Fousteri and Mullenders 2008), base excision repair (BER) (Sancar 1996; Parikh et al. 
1998) and mismatch repair (MMR) (Hsieh and Yamane 2008; Longley, Pierce, and 
Modrich 1997; Jiricny 2006) (see Figure 3). 
                         
Figure 3. DNA damage and different DNA repair pathways. 
 
DNA damage that is not repaired before the S phase acts as an obstacle for the replication, 
which can lead to replication stalling.  The stalled replication fork is unstable; it can break, 
which results in double-strand breaks (DSB), chromosomal aberrations and genomic 
rearrangements that threaten the viability of the cell or the organism (Negrini, Gorgoulis, 
and Halazonetis 2010; Shen 2011; Pikor et al. 2013; Macheret and Halazonetis 2015). 
DNA damage tolerance (DTT) pathways specialize in the rescue of the stalled replication 
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fork. There are two major DTT pathway exist first is error-prone TLS and other is error-
free template switching. The TLS is characterized by the switching of classical DNA 
polymerases to low-fidelity translesion DNA polymerases (TLS). In contrast, template 
switching is proposed to use a recombination-like mechanism by which the nascent DNA 
of the sister chromatid is utilized as a temporary template for replication (Branzei 2011) 
(Figure 4). TLS polymerases are so-called Y-family polymerases such as Pol η, Pol ι, Pol 
κ and Rev1 (Hoitsma et al. 2020). These polymerases have a wider active center; thus, 
they can incorporate nucleotides across the damaged ones (Shcherbakova and 
Fijalkowska 2006; Lehmann et al. 2007). TLS polymerases can introduce nucleotides in 
an error-free or in an error-prone way. In an error-prone way, incorporation of the wrong 
nucleotide or lesion bypass can lead to mutagenesis and carcinogenesis.  
 
Figure 4. Schematic representation of major DNA repair processes at stalled replication 
forks. Mutagenic agents damage DNA triggering monoubiquitination of proliferating cell 
nuclear antigen (PCNA) by the E1 ubiquitin-activating enzyme Uba1, the E2 ubiquitin-
conjugating enzyme Rad6 and the E3 ubiquitin ligase Rad18. Monoubiquitinated PCNA 
activates translesion DNA synthesis (TLS), an error-prone DNA damage tolerance 
process. Monoubiquitinated PCNA can undergo subsequent polyubiquitination in the 
presence of Mms2, Ubc13 and HLTF or SPRH, which initiates error-free template 
switching. 
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1.4. PCNA  
Proliferating cell nuclear antigen (PCNA) belongs to the family of DNA sliding clamps 
(β clamp), which is highly conserved. PCNA is a homotrimer, which encircles the DNA 
and is able to move freely in both directions. PCNA has two globular domains, connected 
by an ICDL inter-domain connecting loop (Figure 5) (Krishna et al. 1994).  PCNA acts 
as a processivity factor for DNA polymerases. It also has a key role in the regulation of 
DNA damage tolerance pathways. PCNA is loaded onto DNA with the help of a protein 
complex called replication factor C (RFC) (Majka and Burgers 2004).  
Figure 5. Ribbon diagram of the PCNA trimer (PDB ID: 1PLQ) shown from the front 
view and the side view. Domain 1 is blue, domain 2 is green and the inter-domain 
connecting loop (IDCL) is red (Krishna et al. 1994). 
In response to the stalled replication fork, PCNA undergoes monoubiquitination at the 
Lysine 164 (K164)  residue or a polyubiquitin chain gets linked via ubiquitin’s lysine 63 
residue (Kanao and Masutani 2017; Moldovan, Pfander, and Jentsch 2007). PCNA 
monoubiquitination requires three steps that are catalyzed by three distinct enzymes. First, 
ATP-dependent activation of the carboxy terminus of ubiquitin is catalyzed by the E1 (the 
ubiquitin-activating enzyme Uba1) through the formation of a ubiquitin-adenylate 
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intermediate, which then reacts with the active-site cysteine on Uba1, yielding a high-
energy Uba1~ubiquitin thioester intermediate. Second, transfer of the ubiquitin moiety to 
the catalytic cysteine on the E2 ubiquitin-conjugating enzyme (Rad6) occurs to form a 
Rad6~ubiquitin thioester intermediate. Third, ubiquitin is transferred from Rad6 
specifically to the side-chain amine of the K164 residue on PCNA to form a PCNA–
ubiquitin isopeptide bond, mediated by the E3 ubiquitin ligase Rad18 in complex with 
Rad6 (Kanao and Masutani 2017; Leung et al. 2019). 
Monoubiquitination of PCNA triggers the TLS pathway and prevents binding of 
replication factors to PCNA, while polyubiquitination initiates an event called template 
switching (Kanao and Masutani 2017; Leung et al. 2019; Gallo and Brown 2019). 
Interestingly, TLS polymerases (Pol η, Pol ι and Rev1) are themselves substrates for 
monoubiquitination. It has been proposed that modifications may facilitate the sequential 
action of different polymerases. Several scenarios can take place at the stalled replication 
fork. Monoubiquitinated PCNA can recruit TLS polymerases on the basis of their 
capability of introducing nucleotides into the DNA lesion, or monoubiquitinated PCNA 
can specifically recruit TLS polymerases via the ubiquitin-binding sites in these enzymes. 
According to another scenario, monoubiquitination of the first TLS polymerase would 
occur only if it is unable to repair the lesion. The intramolecular interaction between its 
ubiquitin and ubiquitin-binding domain would signal for it to be eliminated as an 
unsuccessful TLS polymerase and another one will be recruited to the lesion. The error-
free mode might be initiated when none of the TLS polymerases are able to heal the lesion; 
thus, the prolonged stalling of the replication fork triggers Rad5-Ubc13-Mms2-dependent 
PCNA polyubiquitination. How exactly the error-free pathway proceeds is currently 
poorly understood  (Moldovan, Pfander, and Jentsch 2007; Bienko et al. 2005). 
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TLS is an error-prone process, since TLS polymerases lack 3’-5’ proofreading activity, 
although there are some TLS polymerases that can replicate DNA lesions without causing 
errors (Livneh, Ziv, and Shachar 2010; Sale 2013; Zhao and Todd Washington 2017; 
Powers and Washington 2018). Polyubiquitination of PCNA is mediated by the E2 
enzyme complex (Mms2–Ubc13) in association with the E3 (Rad5) protein orthologs 
helicase like transcription factor (HLTF) or Smf2 histone linker PHD ring helicase 
(SHPRH) (J. R. Lin et al. 2011; Unk et al. 2010; Gangavarapu et al. 2006; Parker and 
Ulrich 2009), through a pathway that yields a polyubiquitination chain distinct from that 
which serves as a tag for proteasomal degradation. PCNA ubiquitination is reversed by 
ubiquitin-specific peptidase-1, helping to control PCNA ubiquitination levels, TLS and 
template switching. What determines the “decision” of whether PCNA should undergo 
monoubiquitination or polyubiquitination is currently unknown. The lysine 164 residue 
of PCNA has also been found to be capable of undergoing modification by ubiquitin-like 
proteins such as small ubiquitin-like modifier (SUMO), neural precursor cell expressed, 
developmentally down-regulated 8 (NEDD8) and interferon-stimulated gene 15 (ISG15), 
through distinct E1–E2–E3 cascades for each, with some overlap in certain cases (Gali et 
al. 2012; Hoege et al. 2002; Stelter and Ulrich 2003; L. Haracska et al. 2004). However, 
the functions of these antagonistic UBL post-translational modifications of PCNA are 
currently unclear. SUMOylation has been proven to regulate homologous recombination, 
NEDDylation limits recruitment of TLS polymerase η under conditions of oxidative stress 
and ISGylation controls the release of TLS polymerases from PCNA complexes and thus 
helps terminate TLS (Hoege et al. 2002; Guan, Yu, and Zheng 2018; Park et al. 2014). 
These differential modifications appear to finely regulate the complex and diverse 
functions of PCNA. A single PCNA trimer may have different modifications on each 
subunit, thus potentially leading to hybrid complexes of a composite function. 
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1.5. EGCG (epigallocatechin gallate) 
EGCG is the major catechin found in green tea extract. It has three heterocyclic rings that 
favor electron delocalization leading to quenching of free radicals. Green tea polyphenols 
particularly its most active and abundant component epigallocatechin-3-gallate (EGCG) 
has gained a lot of attention as a potential therapeutic agent for preventing 
neurodegenerative, inflammatory diseases and cancer mainly due to their beneficial 
effects on human health (Figure 6, showing various properties and application of EGCG 
(Chu et al. 2017)). It also has redox properties; reacts with reactive oxygen species (ROS). 
It inhibits protein tyrosine nitration induced by oxidative stress in platelet cells. As an 
antioxidant, it can improve the function of mitochondria (Sabetkar et al. 2008). EGCG 
has also been reported to cause self-oxidization and function as a pro-oxidant by 
producing hydroxyl radicals, hydrogen peroxide and quinonoid intermediates causing 
cytotoxicity (Li et al. 2010; Sakagami et al. 2001; G.-Y. Yang 2000; Nakagawa et al. 
2004). EGCG also affects inflammation and other immune responses (R. Singh, Akhtar, 
and Haqqi 2010). Inflammation triggers the release of proinflammatory cytokines, 
reactive oxygen species (ROS) and reactive nitrogen species (RNS). ROS/RNS are related 
to the activation of transcription factor NF-κB and activator protein (AP-1), which 
upregulate the expression of a variety of inflammatory genes. EGCG has been shown to 
inhibit transcription factor NF-κB and  AP-1 to downregulate the expression of iNOS and 
COX-2 by scavenging the NO, peroxynitrite and other ROS/NOS and decreases the 
production of inflammatory factors (Kamata and Hirata 1999; Nagai et al. 2002; E. 
Tedeschi, Suzuki, and Menegazzi 2002; Elisa Tedeschi et al. 2004). 
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Figure 6. Cartoon showing the application and properties of EGCG (Chu et al. 2017). 
 
In a number of studies, EGCG has been shown to have antifibrosis properties (Yasuda et 
al. 2009; M. C. Zhen et al. 2006; Weber et al. 1994; Kitamura et al. 2012). EGCG acts by 
blocking the translocation of NF-κB from the cytoplasm to the nucleus. Hepatic fibrosis 
is one of the many complications of chronic liver diseases, which leads to hepatic cirrhosis  
(Lee et al. 2012; Moses et al. 2015). In hepatic cirrhosis and hepatocarcinoma, it has been 
observed that stellate cells are the major source of extracellular matrix (Friedman and 
Bansal 2006; Friedman 1997; 1999). EGCG has inhibitory activity on the activation and 
proliferation of hepatic stellate cells and the biosynthesis of collagen in rat models  
(Nakamuta et al. 2005; Higashi et al. 2005; Sakata et al. 2004). EGCG has been very 
effective and useful in many oral treatment studies mainly due to its anti-inflammatory 
effect and inhibition of bone absorption ability (C. Y. Wang, Tani-Ishii, and Stashenko 
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1997; J. Y. Hong et al. 2015; Shin et al. 2014; Cho et al. 2013; M. chuan Zhen et al. 2007; 
Kostopoulos and Karring 1994). EGCG also exhibits a strong anticancer activity, which 
has been reported by various laboratories (P. Wang, Henning, and Heber 2010; 
Thangapazham et al. 2007; Zaveri 2006). EGCG inhibits many cell signaling pathways 
that are involved in cancer development (Khan et al. 2006; J. Zhang et al. 2016). It has 
been reported in many in vitro studies that EGCG has inhibitory effects on growth and 
induces apoptosis in many human cancer cell lines such as colon, breast, lung, leukemic 
and melanoma (Khan et al. 2006; Aggarwal and Shishodia 2006; J. Zhang et al. 2016). 
EGCG is active in inducing apoptosis and inhibiting metastasis in a variety of cancer cell 
lines via cell cycle arrest or by activation of the MAP kinase cascade (J. K. Lin et al. 
2000).  
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2.  Goals and Objectives 
 
The main goal of the project was to develop various high-throughput step-specific PCNA 
ubiquitination assays and discover modulators of the PCNA ubiquitination reaction 
cascade. PCNA ubiquitination is a key early event in DNA damage tolerance processes, 
it recruits TLS polymerases at stalled replication fork. The TLS polymerases are 
inherently error-prone and they can lead to mutagenesis and carcinogenesis. So, PCNA 
ubiquitination is a potential therapeutic target in combination with currently known cancer 
therapeutics. 
The following aims were envisaged: 
• To develop a robust, reliable and sensitive high-throughput assay to quantitatively 
measure PCNA ubiquitination, based on the amplified luminescent proximity 
homogeneous assay (Alpha) technology. 
• Carry out screening of chemical libraries to discover modulators of the PCNA 
ubiquitination reaction. 
• Hit characterization from screening and structure-activity relationship (SAR) 
studies. 
• To develop secondary assays based on the Alpha system for secondary screening 
to reveal the specific step and protein targeted in the reaction. 
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3. Materials and Methods 
 
3.1. Plasmid constructs and proteins 
3.1.1. His-Uba1 
His-tagged human Uba1 in the pET3a bacterial expression vector (Addgene plasmid 
#63571) was expressed in Escherichia coli strain BL21-CodonPlus(DE3)-RIL (Agilent). 
The cells were centrifuged and washed in 1× phosphate-buffered saline (PBS). The cell 
suspensions were dropped into liquid nitrogen and the resulting frozen beads were ground 
with a SPEX SamplePrep 6775 Freezer/Mill. The lysates were centrifuged and the 
supernatant was applied to Ni-NTA agarose (Machery-Nagel) column. Following 
repeated washings, the protein was eluted from the column with 250 mM imidazole, then 
dialyzed against 20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 10% glycerol, 0.01% NP-40 
and 1 mM freshly added dithiothreitol (DTT). The concentrations were determined by 
measuring absorbance at 280 nm using a NanoDrop ND 1000 spectrophotometer 
instrument. The extinction coefficient of proteins was determined by using the ProtParam 
tool (https://web.expasy.org/protparam/). Finally, by using the Beer-Lambert Law 
concentrations were calculated.  
3.1.2. FLAG-Uba1 
FLAG-tagged human Uba1 was introduced into the pBJ842 yeast expression vector with 
the Leu marker. The FLAG-Uba1 was expressed in S. cerevisiae BJ5654 strain. The cells 
were collected at OD 0.8-1, centrifuged and washed with 1x PBS buffer. The cells were 
broken using a cryogenic method (SPEX cryogenic 6775 freezer/mill). Cell pellets were 
cleared by centrifugation to remove cell debris. The supernatant was transferred onto 
separation columns containing glutathione Sepharose 4B beads (GE Healthcare). The 
lysate was allowed to pass through the column followed by washings. The protein was 
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eluted from the column by incubating with PreScission Protease. The concentration was 
determined as mentioned above. 
3.1.3. Rad6-Rad18 dimer 
Both human Rad6B and GST-fused human Rad18 constructs (each cloned into the 
pBJ842 yeast expression vector, which contains Leu and Trp auxotrophic markers) were 
introduced into the S. cerevisiae BJ5654 strain. The cells were grown in omission media 
(–Leu, –Trp), then collected when reaching OD600 0.8–1, centrifuged and washed with 1× 
PBS. The cells were resuspended in yeast lysis buffer consisting of 50 mM HEPES, pH 
7.5, 50 mM KCl, 267 mM NaCl, 10% sucrose, 0.5 mM EDTA and 2.8 mM β-
mercaptoethanol. The cell lysate was then dropped into liquid nitrogen, ground with a 
SPEX SamplePrep 6775 Freezer/Mill, collected into 1.5 ml microcentrifuge tubes and 
centrifuged. The supernatant was applied to a glutathione Sepharose 4B (GE Healthcare) 
column, followed by repeated washings in 20 mM Tris-HCl, pH 7.5, 10% glycerol, 0.01% 
NP-40 and 1 mM DTT at progressively lower NaCl concentrations (3× 500 mM, 3× 250 
mM, 1× 150 mM). The GST moiety was cleaved with PreScission Protease (GE 
Healthcare) with incubation for 2 h at 4 °C with light shaking and the dimer was eluted 
with a 1.5× bed volume equivalent of 20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 10% 
glycerol, 0.01% NP-40 and 1 mM DTT. The concentration was determined as mentioned 
above. 
3.1.4. RFC complex 
The construct pLANT-2/RIL–RFC[1s+5] was co-transformed with the construct 
pET(11a)–RFC[2+3+4] (Finkelstein et al. 2003) into the E. coli strain BL21-
CodonPlus(DE3)-RIL (Agilent), where RFC1s represents an N-terminally truncated form 
of the large RFC subunit (Gomes and Burgers 2000). The cells were plated and allowed 
to grow under selection with ampicillin (100 μg/ml) and kanamycin (50 μg/ml) overnight. 
23 
 
A single transformant colony was then picked and grown in 2 ml of Luria-Bertani medium 
containing ampicillin (100 μg/ml) and kanamycin (50 μg/ml) at 37 °C for 8 h, then 
inoculated into a starter culture of 2 l of Luria-Bertani medium containing ampicillin (100 
μg/ml) and kanamycin (50 μg/ml) for 16 h. 300 ml of the starter culture was inoculated 
into 2 l of Luria-Bertani medium and grown to OD600 0.8 at 37 °C. The cultures were 
cooled down to 16 °C and induced with 0.5 mM isopropyl-β-D-thiogalactoside for 16 h. 
All further steps were performed at 4 °C. 
The cells were harvested by centrifugation and then resuspended in HEG buffer (30 mM 
HEPES, pH 7.6, 0.5 mM EDTA, 10% glycerol, 5 mM β-mercaptoethanol) containing 150 
mM NaCl. To lyse the cells, lysozyme was added to 0.4 mg/ml and the cells were 
subjected to three freeze-thaw cycles, followed by mechanical shearing through a 
hypodermic needle. The cell lysate was treated with Benzonase endonuclease, purity 
grade II (Merck), according to the manufacturer’s protocol. The cell lysate was clarified 
by centrifugation. RFC was purified by chromatography over an SP-Sepharose column 
(bed volume of 6 ml), pre-equilibrated with HEG with 50 mM NaCl, followed by a wash 
with 60 ml of HEG buffer containing 50 mM NaCl. Elution was carried with a gradient 
of 50–1,000 mM NaCl in a 60 ml HEG buffer. Peak fractions were collected, pooled, then 
diluted with Ni-NTA buffer (30 mM HEPES, pH 7.6, 20 mM imidazole, 500 mM NaCl, 
10% glycerol, 5 mM β-mercaptoethanol). The resulting sample was then applied to a Ni-
NTA agarose (Machery-Nagel) column (bed volume of 500 µl), pre-equilibrated with Ni-
NTA buffer. The column was then washed with 5 ml of Ni-NTA buffer and proteins were 
eluted by a three-step gradient (100 mM, 250 mM and 500 mM imidazole), each with 1.5 
ml overall volume. Fractions were tested for PCNA loading ability and peak fractions 
were aliquoted, frozen in liquid N2 and stored at –80 °C until subsequent use. The 
concentration was determined as mentioned above. 
24 
 
3.1.5. GST-Ubiquitin 
GST-tagged human ubiquitin was expressed in the E. coli strain Dh5α. The cultures were 
grown in LB medium in the presence of ampicillin at 37° C on a shaker. The cells were 
induced with 200 µM IPTG for 2 h at 37° C on a shaker. The cells were centrifuged and 
washed in 1x PBS buffer. The washed cells were ground with a cryogenic method using 
a SPEX cryogenic 6775 Freezer/Mill. The lysate was centrifuged at high speed and the 
clear cell lysate supernatant was transferred onto separation columns containing 
glutathione-sepharose 4B beads. The lysate was allowed to pass through the column 
followed by washings. The protein was eluted from the column using 20 mM reduced 
glutathione. The concentration was determined as mentioned above.  
3.1.6. FLAGPCNA 
Constructs of human PCNA bearing GST and FLAG tags was cloned into the pBJ842 
yeast expression vector. It waws used to prepare FLAG-tagged PCNA, with subsequent 
expression in the S. cerevisiae BJ5654 str-ain and purification with cleavage of the GST 
moiety, as above. The concentration was determined as mentioned above.  
3.1.7. FLAG-Rad6 and FLAG-Rad18 
Constructs were generated with the Gateway cloning technology (Life Technologies). 
Human Rad6 and human Rad18 cDNA sequences from entry constructs were recombined 
into a modified pGEX-6P-1 (Amersham) destination vector bearing GST and FLAG tags 
with a Gateway cassette via the LR Clonase II reaction (Invitrogen). Proteins were 
overexpressed in the E. coli strain BL21-CodonPlus(DE3)-RIL (Agilent). The proteins 
were purified with the removal of the GST moiety, as above. The concentration was 
determined as mentioned above.  
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3.2. Plasmids, antibodies and other supplies  
The pUC19 plasmid was transformed into Dh5α cells. The cells were cultured for 16 h at 
37°C on a shaker. Cells were collected from overnight culture by centrifugation and the 
plasmid was purified (Qiagen QIAprep Spin Miniprep Kit). The plasmid was nicked by 
digestion with the Nt. BstNBI enzyme overnight at 50°C. The digested plasmid was 
checked using the agarose gel electrophoresis technique. The biotinylated human 
ubiquitin was purchased from Boston Biochemicals/R&D Systems (UB-570). 
Streptavidin donor and anti-FLAG acceptor AlphaLisa and AlphaScreen beads were 
purchased from PerkinElmer. Anti-FLAG M2 monoclonal antibody conjugated to 
horseradish peroxidase (HRP) was purchased from Sigma-Aldrich. Anti-GST HRP-
conjugated antibody was purchased from GE healthcare. Anti-DNA polymerase delta 
catalytic subunit and anti-tubulin antibody were purchased from Santa Cruz 
Biotechnology. GST-tagged proteins were digested by PreScission Protease as per 
requirement. The chemical library was purchased from Avicor Ltd. The screening hit 
EGCG and its 11 analogs were purchased commercially from Avicor, Selleck Chemicals 
and Adooq Biosciences (Supplementary Table 1). EGCG and its analogs were dissolved 
in DMSO with final concentration of 50 mM for in vivo experiments and 10 mM for in 
vitro experiments.  
3.3. PCNA ubiquitination  
The PCNA loading and ubiquitination cascade was reconstituted in 96-well white round-
bottom polypropylene plates (Greiner) in a buffer consisting of 40 mM Tris-HCl, pH 7.5, 
8 mM MgCl2 and 10% glycerol with 2.5 nM nicked circular pUC19, 50 nM RFC, 50 nM 
Uba1, 250 nM Rad6–Rad18 dimer, 50 nM FLAG-PCNA and 250 nM biotin-ubiquitin 
(final concentrations). Compounds were added to the samples, with pre-incubation for 
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15 min at 25 °C before the addition of ATP to a final concentration of 2 mM (to initiate 
the reaction cascade), followed by incubation for 2 h at 25 °C. The reactions were then 
terminated by the addition of EDTA to 20 mM for Alpha assays or Laemmli sample buffer 
for western blot analyses or for silver staining. For Alpha assays, reaction mixtures were 
diluted 10x in buffer containing 20 µg/ml streptavidin-conjugated donor beads and anti-
FLAG antibody-conjugated acceptor beads in opaque white microplates under low-light 
conditions or green light, as recommended by the Alpha bead manufacturer, PerkinElmer. 
The plates were read on a Tecan Spark microplate reader at 23 °C. For western blot 
analyses, FLAG-PCNA was detected with anti-FLAG antibody and quantitation from the 
western blot images were performed with the NIH Image J software (Schneider, Rasband, 
and Eliceiri 2012) and then analyzed with the GraphPad Prism software. 
Note: The protein concentrations for the alpha based PCNA ubiquitination assay 
mentioned above were further optimized and miniaturized and are described in Results 
and Conclusions section. 
3.4. Uba1~Ubiquitin thioester assay 
50 nM FLAG-Uba1 was charged with 150 nM biotin-ubiquitin (150 nM Uba1 and 450 
nM biotin-ubiquitin for gel-based assay) in the presence of a buffer consisting of 40 mM 
Tris-HCl, pH 7.5, 8 mM MgCl2 and 10% glycerol by adding 2 mM ATP. The reaction 
was incubated for 30 minutes at 25 °C. The reaction was stopped by adding 20 mM of 
EDTA or Laemmli sample buffer for western blot analyses or silver staining,  and 10 
µg/ml Acceptor and Donor beads in a buffer consisting of 25 mM HEPES, pH 7.5, 100 
mM NaCl, 0.1 % Tween 20 was added with 10x dilution. The reaction was incubated for 
4 h at 25 °C. 
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3.5. Rad6-Ubiquitin thioester assay 
Variable concentrations of FLAG-Rad6, with biotin-ubiquitin held at 150 nM and 
variable concentrations of biotin-ubiquitin, with FLAG-Rad6 held at 50 nM, were each 
separately varied while holding the other parameters under otherwise identical reaction 
and assay conditions in a buffer of 40 mM Tris-HCl, pH 7.5, 8 mM MgCl2 and 10% 
glycerol. Uba1 concentration was 50 nM in these experiments. The reactions were 
initiated by the addition of 2 mM ATP for a final volume of 20 µl, incubated for 30 min 
at 25 °C. The reaction was stopped by adding 20 mM of EDTA and 10 µg/ml Acceptor 
and Donor beads in a buffer consisting of 25 mM HEPES, pH 7.5, 100 mM NaCl, 0.1% 
Tween 20 was added with 10x dilution. The reaction was incubated for 4 h at 25 °C.   
Once satisfactory starting conditions were found, the overall reaction was conducted in 
two separate steps, which allows screening for direct inhibitors of Rad6~ubiquitin 
thioester formation whose mechanism is not just secondary to inhibition of 
Uba1~ubiquitin thioester formation. For initial pre-charging of Uba1 with biotin-
ubiquitin, 100 nM His-Uba1 was combined with 300 nM biotin-ubiquitin, with the 
reaction initiated by the addition of ATP to 2 mM, followed by incubation for 30 min at 
25 °C. The reaction sample was then combined with an equal volume of 100 nM FLAG-
Rad6 (which can be pre-incubated with compounds for screening for direct Rad6 
inhibitors), for final concentrations of 50 nM His-Uba1, 150 nM biotin-ubiquitin and 50 
nM FLAG-Rad6. The mixture was incubated for another 10 min at 25 °C, with the 
remaining procedures as before. 
3.6. Rad6-Rad18 interaction assay 
25 nM FLAG-Rad6 and 25 nM His-Rad18 (equimolar) concentrations tested in 2x 
increments under otherwise identical reaction and assay conditions in a buffer of 40 mM 
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Tris-HCl, pH 7.5, 8 mM MgCl2 and 10% glycerol. The reaction was incubated at 25 °C 
for 30 min, then diluted by a factor of 10× in a buffer consisting of 25 mM HEPES, pH 
7.5, 100 mM NaCl, 0.1% Tween 20 and 20 mM EDTA with donor and acceptor beads at 
10 µg/ml. After 2 h of incubation at 25 °C in the dark, the plates were read on the Tecan 
plate reader at 23 °C. 
3.7. Alpha assay for Rad18 auto-ubiquitination 
FLAG-Rad18 and biotin-ubiquitin concentrations were separately varied under otherwise 
identical reaction and assay conditions in a buffer of 40 mM Tris-HCl, pH 7.5, 8 mM 
MgCl2 and 10% glycerol. Uba1 was held constant at 50 nM and Rad6–Rad18 dimer at 
100 nM. The reaction was incubated at 25 °C for 1 h, then terminated and diluted by a 
factor of 10× in a buffer consisting of 25 mM HEPES, pH 7.5, 100 mM NaCl, 0.1% 
Tween 20 and 20 mM EDTA and 1 mM freshly added DTT, with donor and acceptor 
beads at 10 µg/ml. After 4 h of incubation at 25 °C in the dark, the plates were read on 
the Tecan plate reader at 23 °C. 
3.8 NMR analysis 
NMR spectra were acquired with a Bruker Avance 600 MHz spectrometer equipped with 
a 5 mm z-gradient CP-TCI triple-resonance cryoprobe at 303 K. EGCG and Uba1 were 
dissolved in 20 mM phosphate-buffered saline at pH 7.4 (90% H2O, 10% D2O), 
containing 150 mM NaCl and 0.02% NaN3. To prevent EGCG oxidation, 1 mM tris (2-
carboxyethyl)phosphine was added to the solutions. EGCG and Uba1 concentrations were 
400 μM and 4 μM, respectively. All the spectra were acquired with excitation sculpting 
solvent suppression pulse scheme. In STD experiments, 40 equally spaced 50 ms 
Gaussian-shaped pulses were used for the selective saturation of the protein, thus, the total 
saturation time was 2 s. The on-resonance irradiation and the off-resonance saturation 
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frequencies were set at 0.86 ppm and 40.0 ppm, respectively. A total of 2k scans were 
collected for each pseudo-2D experiment. 2D NOESY experiments were acquired with 
128 increments and a mixing time of 100 ms. As a control, all the experiments were 
repeated for a sample containing EGCG at the same concentration but in the absence of 
the protein. 
3.9 Cell culture 
For cellular experiments, HEK 293FT cells (a fast-growing SV40 large T antigen-
transformed strain of HEK 293 cells designed for enhanced transgene expression in 
transient transfections) were grown in growth medium consisting of Dulbecco’s modified 
Eagle’s medium (DMEM; Sigma-Aldrich) supplemented with 10% fetal bovine serum 
(FBS; Gibco) in a humidified cell culture incubator at 37 °C with 5% CO2. 
3.10 Cell survival assay 
HEK 293FT cells were evaluated for survival following compound treatments by the 
Alamar Blue (resazurin) assay. Cells were plated onto 96-well plates at 4.8 × 
104 cells/well in 0.5% FBS-containing DMEM at 37 °C and 5% CO2. After 24 h, 
compounds were added. After 24 h of treatment, resazurin was added to a final 
concentration of 0.12 mM. Following 4 h of incubation, conversion to the resorufin 
product was measured (with excitation at 542 nm and emission at 590 nm) on a 
fluorescence plate reader. 
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3.11 Cell transfections 
HEK 293FT cells (1.5 × 106) were plated onto 6-cm plates in 5 ml of DMEM with 10% 
FBS and allowed to grow for 24 h at 37 °C and 5% CO2. For transfections, 6 μg of plasmid 
DNA (an empty vector containing FLAG-tag sequence only, FLAG-Uba1, or FLAG-
ubiquitin) and 10 μl of Lipofectamine 2000 were used for each plate. The DNA and the 
reagent were diluted separately in 500 μl of Opti-MEM (Gibco) and each was mixed by 
vortexing. After 5 min of incubation, the two tubes were combined and incubated for 
another 20 min. Prior to the addition of the transfection solution to the cells, the medium 
was replaced with 4 ml of Opti-MEM. The transfection solution was then added dropwise. 
After 3 h of incubation, the medium was changed to 0.5% FBS-containing DMEM and 
the cells were plated for cell survival experiments, as above 
3.12 Cellular ubiquitination  
HEK 293FT cells were plated in 6-well plates at 8 × 105 cells/well in DMEM with 0.5% 
FBS. After 24 h at 37 °C and 5% CO2, EGCG was added; then 30 min later, MG132 was 
added to a concentration of 50 μM, with incubation for another 30 min (for a total of 1-h 
EGCG treatment). Cells were harvested and whole-cell lysates were prepared in RIPA 
lysis buffer containing protease inhibitor cocktail (SIGMAFAST from Sigma-Aldrich) 
and sonicated. Equivalent loadings of total proteins for each treatment, as determined by 
Bradford assay of each extracted sample, were subjected to electrophoresis on 8% SDS-
polyacrylamide gels and western blot analysis, probed with anti-ubiquitin antibody, then 
stripped and reprobed with an anti-β-tubulin antibody. 
3.13 Statistical analysis 
In a high-throughput assay (HTS) large chemical library was screened, hits were 
identified on the basis on following statistical parameters:  
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Signal-to-noise (S/N) ratio is an indication of the degree of confidence with which signal 
can be regarded as real. In addition to S/N Signal-to-background (S/B) ratio is also 
considered. The S/N ratio is not sufficient to decide whether the assay is good.  
 
                  
 
The inherent problem of considering S/N and S/B cannot define the level of variability. 
Hence in these scenarios, z-factor is considered. The z-factor is defined in terms of four 
parameters: the means and standard deviation of both the positive and negative controls. 
Given these values, the Z-factor is defined as:                
  
Z-factor is sensitive to outliers, a variation is known as the robust z-score, which 
substitutes the outlier-insensitive median and median absolute deviation (MAD) for mean 
and standard deviation in the z-score calculation, is generally considered preferable 
for HTS. We considered z-prime and z-robust both for hit selection in our screening (J. 
H. Zhang, Chung, and Oldenburg 1999; N., C., and Che 2013).  
Another measurement taken for quality control and hit selection is considering strictly 
standardized mean difference (SSMD) and Signal window values. SSMD is the mean 
divided by the standard deviation of the difference between two random groups. Signal 
window values, this is a more indicative measure of the data range in an HTS assay than 
32 
 
the above parameters. Two alternative versions of the SW are presented below (N., C., 
and Che 2013).  
 Positive (Cpos) and negative (Cneg) 
controls 
Half-maximal inhibitory concentration IC50 is a measure of the effectiveness of a 
substance in inhibiting a specific biological or biochemical function.  
To calculate S/N, S/B, SSMD, Z factor and signal to window values an excel sheet 
template was prepared which automatically calculated these values. All the Curve fitting, 
IC50 calculations were carried out using the GraphPad Prism 8.0–8.2 software.   
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4. Results and Conclusions 
4.1. Development of a high-throughput screening assay to discover 
modulators of PCNA ubiquitination 
To discover small-molecule inhibitor for PCNA ubiquitination, we adapted amplified 
luminescent proximity homogeneous assay (Alpha) technology for assay development for 
PCNA ubiquitination. The assay consists of a reconstituted system with biotin-ubiquitin, 
hUba1, FLAG-tagged PCNA, RFC, Rad6-Rad18 dimer and nicked circular pUC19 
plasmid (Lajos Haracska et al. 2006). We have developed a quantitative assay for PCNA 
ubiquitination based on a PerkinElmers Alphascreen/AlphaLisa system (Figure 7a), with 
a wide dynamic range and high signals in the positive control (with ATP) relative to the 
negative control (without ATP). We have also confirmed it by Western blot analysis 
(Figure 7b). The PCNA undergoes monoubiquitination at Lys164 residue, we found 
monoubiquitination of PCNA at K164 residue, as the K164 mutant did not show 
ubiquitination (Lajos Haracska et al. 2006; Unk et al. 2008). 
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Figure 7. Reconstituted assay for PCNA ubiquitination. a. High-throughput screening 
system for in vitro PCNA ubiquitination, based on AlphaScreen/AlphaLISA 
technology.  Note: Unlike in this simplified diagram, each of the three subunits of the 
PCNA trimer bears a FLAG tag and each PCNA molecule is monoubiquitinated on K164 
at saturation in the reaction; thus, higher bead-to-trimer stoichiometry will occur than 
indicated (in principle, three donor and three acceptor beads per complex, depending on 
steric factors). b. Upper panel: Quantitative measurement of PCNA ubiquitination by the 
Alpha system for non-initiated (−ATP) and initiated (+ATP) ubiquitination reaction 
cascades. Data represent mean and standard deviation (SD) for six independent 
experiments for Alpha signal values in counts per second (cps) following incubation 
without or with ATP for 2 h, under conditions described in Materials and Methods. Lower 
panel: Representative western blot of samples incubated without or with ATP for 2 h 
probed with anti-FLAG antibody, as described in Materials and Methods, showing non-
ubiquitinated FLAG-PCNA (lower band) and ubiquitinated FLAG-PCNA (upper band).  
  
4.2. Optimization of the PCNA-ubiquitination-based Alpha assay  
Initially, we developed the Alpha assay with the protein concentrations described in the 
Materials and Methods section, so that we can compare the efficacy of PCNA 
ubiquitination in alpha assay with western blot analysis. Starting from the conditions we 
optimized for Western blot analysis and initial PCNA ubiquitination alpha assay, we 
further refined the reconstituted system for more sensitive Alpha technology to reduce the 
consumption of various resources. The overall Alpha assay can be viewed as composed 
of two main parts: first, the biochemical PCNA ubiquitination reaction that generates the 
proximity relationship to be assayed; second, the procedures for Alpha detection, which 
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involves dilution of the initial samples with the addition of beads and then the actual 
detection itself. Both of these major steps of the overall assay were pursued for 
optimization. We started the optimization by titrating the concentrations of the biotin-
ubiquitin, FLAG-PCNA, RFC, Uba1 and  Rad6-Rad18 dimer. We titrated the individual 
protein in each experiment by keeping other components of the PCNA ubiquitination 
reaction constant (Figure 8). DNA can also be the target for many small molecules, to 
make assay more sensitive we also titrated pUC19 concentration by keeping other 
components constant as described previously (Figure 9). Based on the experiments 
(Figures 8 and 9), we chose 10 nM RFC, 10 nM Uba1, 100 nM Rad6–Rad18 dimer, 50 
nM FLAG-PCNA, 250 nM biotin-ubiquitin and 2 nM pUC19 as optimal concentrations. 
The experiments performed afterward thus conducted with these concentrations. After the 
optimization of proteins and DNA, PCNA ubiquitination reaction kinetics was performed 
(Figure 10) and we found 2 h incubation gives the best signal range. 
To find out whether we can miniaturize the PCNA ubiquitination reaction volumes, we 
performed PCNA ubiquitination reactions in 5 µL, 10 µL and 20 µL (Figure S1). We 
found out that a 20 µL reaction gives the best signal range. We also tested donor and 
acceptor bead incubation times for the detection of ubiquitinated PCNA and we found out 
that 4 h works the best (Figure S2). After completion of the PCNA ubiquitination reaction, 
alpha beads are added which dilutes the reaction. We tested dilution factors for the 
detection of ubiquitinated PCNA in the alpha assay and we found out 10x dilution gives 
the best signals (Figure S3). The donor and acceptor bead concentrations, donor and 
acceptor bead ratios and donor/acceptor beads order of addition experiments were 
performed to detect the best alpha signal range for the detection of ubiquitinated PCNA 
(Figure S4, S5 and S6) and we found out that 10 µg/ml beads concentration, an equimolar 
ratio of beads (i.e. 10 µg/ml each) and addition of donor and acceptor beads at the same 
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time gives the best signal range. In the end, we sought to answer other questions such as 
tolerance of DMSO and ATP concentration (Figure S7 and S8).  
 
Figure 8. Optimization of protein components in the Alpha assay for PCNA 
ubiquitination. a FLAG-PCNA, b biotin-ubiquitin (Bio-Ub), c RFC (left and right panels 
are different concentrations range from separate experiments), d Uba1 and e Rad6–Rad18 
dimer, with other components in each case held constant as noted in Materials and 
Methods. 
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Figure 9. Nicked pUC19 plasmid concentration variation in the PCNA ubiquitination 
assay. Different nicked pUC19 plasmid concentrations of 0 nM, 0.5 nM, 1 nM, 2 nM, 5 
nM and 10 nM were tested, with the other reaction components held constant as described 
in Materials and Methods, with the alpha assay carried out otherwise as described in the 
Materials and Methods section. 
 
Figure 10. PCNA ubiquitination reaction kinetics under final optimized conditions. The 
reaction with optimized conditions based on Figure 8 and 9 was stopped at different time 
intervals from 0 to 6 h by adding 20 mM EDTA, followed by alpha assay carried out 
otherwise as described in the Materials and Methods section. 
4.3. Final optimized conditions for the high-throughput Alpha assay 
for PCNA ubiquitination 
Based on the sum of all the optimized experiments for both the PCNA ubiquitination 
reaction and the Alpha detection step of the overall assay, the final conditions were chosen 
to balance both optimal assaying and material usage concerns for the PCNA 
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ubiquitination assay. The final PCNA ubiquitination reaction with 10 nM RFC, 10 nM 
Uba1, 100 nM Rad6–Rad18 dimer, 50 nM FLAG-PCNA, 250 nM biotin-ubiquitin and 2 
nM nicked pUC19 was initiated by addition of 2 mM ATP in a reaction volume of 20 µl 
in 96-well plates. The reaction was incubated for 2 h at 25 °C and after that diluted by a 
factor of 10× in Alpha buffer containing donor and acceptor beads (10 µg/ml each) and 
20 mM EDTA, with incubation of 4 h in the dark at 25 °C, followed by the Alpha 
detection. We found that Z factors had typical values for any given plate between 0.6 and 
0.9, particularly by robust statistics, which is less sensitive to outliers than standard 
statistics, when comparing positive (with ATP) and negative (without ATP) control 
values, indicating suitability for high-throughput screening. Per plate, strictly 
standardized mean difference (SSMD) values, signal-to-noise ratios, signal-to-
background ratios and signal window values were generally also good. The alpha assay 
sensitivity was also tested by using the PCNA ubiquitination reaction at scaling factors of 
0.25×, 0.5×, 1×, 2×, 4× and 8× for the optimized concentrations of all proteins and DNA 
(where 1× represents the optimized concentrations) for alpha assay (Figure 11).  
 
 
 
 
Figure 11. Representative graph of the 
sensitivity of the Alpha assay for the 
detection of ubiquitinated PCNA. Reactions 
were conducted at scaling factors of 0.25×, 
0.5×, 1×, 2×, 4× and 8× for the optimized 
concentrations of all proteins and DNA 
(where 1× represents the optimized 
concentrations). The PCNA ubiquitination 
cascade was initiated by the addition of ATP 
to 2 mM, with subsequent incubation for 2 h 
at 25 °C and termination by the addition of 
EDTA to 20 mM and followed by an 
optimized Alpha assay (as optimized 
above). 
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4.4. EGCG inhibits PCNA ubiquitination 
We have screened a chemical library from Avicor Ltd from which we have identified 
EGCG as a potential bioactive hit that inhibits PCNA ubiquitination (PCNA 
ubiquitination was the first alpha assay that we developed on a demo instrument from 
which we discovered EGCG. Later we characterized EGCG and its 11 analogs in a gel-
based assay because the demo instrument was gone and we were waiting for the Tecan 
Spark Alpha scanner. Once, we received the alpha reader the re-optimization and 
miniaturization of the alpha assay were performed followed by the validation of EGCG 
and its analogs for the IC50 on it, see in Supplementary Table 3). The confirmation of 
EGCG’s inhibitory activity by the western blot probed with anti-FLAG antibody. The 
Western blot showing the dose-response for inhibition of PCNA ubiquitination by EGCG 
(0.0122 to 6.25 μM in concentration increments of 2×), with a final DMSO carrier solvent 
concentration of 2% in all cases. Samples were pre-incubated with EGCG for 15 min 
before the addition of ATP, then further incubated for 2 h. Negative and positive controls 
consisted of parallel samples incubated with DMSO alone in the absence (−) or presence 
(+) of ATP, respectively (Figure 12). 
 
Figure 12. Western blot analysis showing dose-response for EGCG in PCNA 
ubiquitination. Representative dose-response western blot probed with anti-FLAG 
antibody showing the inhibition of PCNA ubiquitination by EGCG (0.0122 to 6.25 μM in 
concentration increments of 2×).  
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4.5. Dose-response analysis for different compounds in PCNA 
ubiquitination  
The dose-response experiments were performed with EGCG and its analogs using western 
blot analysis. The relative percentage of PCNA ubiquitination in a western blot was 
calculated according to (FLAG-PCNA–ubiquitin)/ (FLAG-PCNA + FLAG-PCNA–
ubiquitin) × 100% for each lane internally from different independent experiments, as 
indicated for each case (Figure 14 and also in Supplementary Table 2 along with IC50 
values). Dose-response experiments revealed that EGCG inhibits PCNA ubiquitination 
with a half-maximal inhibitory concentration (IC50) of 228 nM.  
We considered 500 μM with DMSO concentration of 2%, as a threshold and compounds 
which did not show inhibition at this dose were concluded as inactive (see figure 13). The 
negative and positive controls consisted of 2% DMSO alone without or with ATP, 
respectively.  
                                        
Figure 13. Compounds showing no inhibitory activity in the PCNA ubiquitination assay 
at 500 μM, with a DMSO concentration of 2% in all cases. Data represent mean ± SD, 
derived from the quantitation of western blot images 
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Figure 14. Dose-response curves for the percentage of PCNA ubiquitination inhibition 
by EGCG and its analogs. The dose-response curves are plotted both linearly and semi-
logarithmically (inset), with a DMSO concentration of 2% in all cases. Data represent 
mean ± SD from 3-7 independent experiments, derived from the quantitation of western 
blot images. 
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4.6. EGCG blocks Uba1-ubiquitin thioester formation 
In an attempt to identify target proteins involved in the ubiquitination pathway, we 
investigated each small step involved in ubiquitination to identify target proteins involved 
in the reaction. We, therefore, looked at a specific step in the ubiquitination cascade and 
found that EGCG directly inhibits the formation of Uba1-ubiquitin thioester formation by 
directly targeting the Uba1 protein. To specifically identify whether it targets ubiquitin or 
Uba1 in the thioester assay, we carried out thioester experiments by the pre-incubation of 
either Uba1 or ubiquitin with EGCG and Myr, respectively. The pre-incubation of Uba1 
alone with EGCG prior to the addition of ubiquitin and ATP leads to absolute inhibition 
of the Uba1-ubiquitin thioester adduct, but not when pre-incubated with ubiquitin first 
(Figure 15). However, myricetin inhibits the formation of Uba1-ubiquitin thioester adduct 
in both cases, irrespective of pre-incubation with either of the proteins (Figure 15). Final 
compound concentrations were 10 μM for EGCG or 50 μM for Myr (with DMSO alone 
as control and a DMSO concentration of 2% in all cases). Following pre-incubation, 
reactions were allowed to proceed for 2 h with ubiquitin, Uba1 and ATP. A comparison 
of results in the absence or presence of DTT as a reducing agent confirms that the 
conjugation is through the reducible thioester. 
 
Figure 15. The effects of EGCG and Myr on Uba1 and ubiquitination are reversible. 
Representative western blots showing that EGCG inhibits Uba1~ubiquitin thioester 
formation when pre-incubated with Uba1 before adding ubiquitin, but not when pre-
incubated with ubiquitin first, while Myr inhibits Uba1~ubiquitin thioester in both cases.  
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4.7. Effects of EGCG and myricetin on Uba1 are reversible 
We conducted reversibility experiments by preincubating Uba1 or ubiquitin 
with EGCG and then washing out unbound compound by serial centrifugal 
filtration, followed by addition of other components to assay for ubiquitination. 
We found that ubiquitination activity recovers upon washout of compound, 
demonstrating that EGCG inhibits Uba1 and consequent ubiquitination in a 
reversible manner (Figure 16). 
 
 
 
 
Figure 16. The effects of EGCG and Myr on Uba1 and ubiquitination are reversible. 
30 μM EGCG and 30 μM Myr (with DMSO alone as control and a DMSO 
concentration of 2% in all cases) were preincubated with Uba1 for 2 h, 
completely washed out by serial centrifugal filtration, and then assayed for 
PCNA ubiquitination activity after addition of other reaction components, with 
detection by Western blot analysis with anti-FLAG antibody. 
 
4.8. Dose-response analysis for Uba1~ubiquitin thioester formation 
The dose-response for the relative percentage of Uba1~ubiquitin thioester formation with 
increasing concentrations of each compound was calculated by SDS PAGE gel silver 
staining (Figure 18). Each value was normalized on a gel-by-gel basis to the parallel 
positive control (DMSO alone with ATP) level of Uba1~ubiquitin thioester conjugate 
formed in each case and from the quantitation of silver-stained SDS-polyacrylamide gels 
of reaction samples without DTT. The compounds with no inhibitory activity at 500 μM 
with a DMSO concentration of 2% in all cases in the gel-based assay are shown in Figure 
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17. The calculated IC50 of EGCG is 1.6 µM and other IC50 values are summarized in 
Supplementary Table 2. 
                                         
Figure 17. Compounds showing no inhibitory activity in Uba1~ubiquitin thioester 
formation at 500 μM in the gel-based assay. The DMSO concentration was 2% in all 
cases. Data represent mean ± SD, derived from quantitation of silver-stained gel images. 
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Figure 18.  Dose-response for EGCG and its analogs in Uba1~ubiquitin thioester 
formation. The dose-response curves are plotted both linearly and semi-logarithmically 
(inset), with a DMSO concentration of 2% in all cases. Data represent mean ± SD for 3-
4 independent experiments, derived from the quantitation of silver-stained gel images.  
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4.9. Nuclear magnetic resonance (NMR) shows that EGCG binds Uba1 
The binding of EGCG to Uba1 was elucidated by ligand-detected 1H NMR techniques. In 
the presence of Uba1, signal intensity loss was observed in the aromatic 1H NMR signals 
of EGCG compared with the control spectrum containing no protein (Figure 19a), which 
can be indicative the dissociation constant (Kd) of the binding is in low  
micromolar. The interaction was also tested by standard saturation transfer difference 
(STD) NMR (M. Mayer and Meyer 2001; Moriz Mayer and Meyer 1999; Meyer and 
Peters 2003; Becker et al. 2018) and transferred NOE (trNOE) experiments. In the STD 
spectrum of EGCG, 1H signals of EGCG could be clearly detected proving ligand binding 
to Uba1 (Figure 19b). The interaction could also be confirmed via trNOE NMR. In the 
presence of Uba1, positive cross-peaks were observed due to the higher cross-relaxation 
rates of EGCG upon protein binding (Figure 19c). In the 2D NOESY spectrum of the 
EGCG control sample, no cross-peaks appeared. 
Both STD and trNOE requires dynamic equilibrium between the free and the bound states 
of the ligand and are sensitive in the Kd range of 10-3–10-8 M. As signal intensity loss of 
EGCG signals was also observed, the NMR measurements support that the dissociation 
constant of the EGCG - Uba1 interaction is in the high nanomolar - low micromolar range 
if a single binding mode is present. Considering the IC50 value of the biological response, 
NMR results strongly suggest that a direct EGCG–Uba1 binding is responsible for the 
activity. 
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Figure 19. NMR reveals that EGCG directly binds Uba1. (a) Aromatic 1H NMR region 
of EGCG in the presence of Uba1 (red) and without protein (black). (b) STD NMR 
spectrum recorded for EGCG in the presence of Uba1, aromatic region. (c) TrNOE 
experiment: no cross-peaks are present in the EGCG control experiment (left), while 
several cross-peaks appeared in the presence of Uba1 (negative NOE due to an 
equilibrium between the free and the bound state of EGCG). The data suggest a Kd in the 
range of high nM to low μM, as discussed in the Results and Conclusions section. 
4.10. Dose-response analysis of cell survival  
To get the IC50 values of EGCG and its analogs we assessed cell viability in HEK 293 
cells. The cells were treated with EGCG and its analogs for 24 h with each compound and 
tested by the Alamar Blue (resazurin) assay relative to parallel-untreated controls. The 
EGCG and its analogs reduce the viability and growth of HEK 293FT cells (Figure 20). 
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The EGCG showed the inhibition with an IC50 value of 220.2 μM (see Supplementary 
Table 2 for the IC50 values of other analogs). 
 
Figure 20. Dose–response for effects on HEK 293 cell survival, after 24-h treatment with 
each compound relative to parallel untreated controls detected by the Alamar Blue 
(resazurin) assay. Data represent mean ± SD for 4-6 independent experiments (as 
indicated along with IC50 values for each case in Supplementary Table 2), plotted both 
linearly and semi-logarithmically (inset), with a DMSO concentration of 2% in all cases. 
4.11. Uba1 or ubiquitin protects the cells from cytotoxic effects of 
EGCG and EGCG reduces the global ubiquitination in cells. 
To investigate whether overexpression of Uba1 and/or ubiquitin protects the cells from 
cytotoxic/cytostatic effects of EGCG. The transfected HEK 293 cells overexpressing 
FLAG-tagged Uba1 or FLAG-tagged ubiquitin exhibited reduced sensitivity to EGCG 
compared to cells transfected with the FLAG-tag containing empty vector alone (Figure 
21). In contrast, the unrelated cytotoxic compound puromycin displayed no differences in 
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apparent toxic potency between normal and Uba1- or ubiquitin-overexpressing cells 
(Figure 21).  
 
 
Figure 21. Overexpression of Uba1 or ubiquitin reduces the sensitivity of cells to the 
cytostatic/cytotoxic effects of EGCG. Overexpression of Uba1 or ubiquitin reduces the 
sensitivity of cells to the cytostatic/cytotoxic effects of the compounds that also have in 
vitro activity against PCNA ubiquitination and Uba1~ubiquitin thioester formation but 
not those without activity. Data represent mean and SD for % cell survival relative to 
parallel controls (DMSO alone) for three independent experiments, with a DMSO 
concentration of 2% in all cases. Higher survival values following compound treatment 
between Uba1- or ubiquitin-overexpressing HEK 293 cells compared to the 
corresponding empty vector-transfected control cells after 24-h compound treatment are 
indicated with an asterisk (p < 0.003 in all cases by unpaired two-tailed Student’s t-tests). 
Treatment concentrations were at the IC50 values initially calculated for each compound 
shown in Supplementary Table 2. 
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          With the evidence from our biochemical and cellular experiments that indicates 
EGCG targets Uba, we were interested to test global ubiquitin conjugates in the whole-
cell lysate. EGCG treatment inhibited the accumulation of ubiquitin-conjugated protein 
species in HEK 293 cells, in response to treatment with the peptide aldehyde proteasome 
inhibitor MG132 (Figure 22). 
 
Figure 22. EGCG inhibits global ubiquitination in HEK 293 cells. Representative western 
blot showing inhibition of global ubiquitination by EGCG in HEK 293 cells. Cells were 
treated with EGCG at 250 μM and 500 μM (with DMSO alone as control and a DMSO 
concentration of 1% in all cases) for 30 min and then MG132 was added to 50 μM. Cells 
were then incubated for another 30 min, for a total EGCG treatment time of 1 h. 
Equivalent loadings of total protein from whole-cell lysates were subjected to western 
blot analysis with anti-ubiquitin antibody and then with anti-β-tubulin antibody as a 
housekeeping protein loading control. 
 
4.12. SAR with EGCG analogs reveals distinct groupings of congeners 
by structure, activity profile and mechanisms of action  
We tested a series of EGCG-related molecules (structures in Figure 23) for potential 
inhibitory activity in the same assays as before: PCNA ubiquitination in vitro (Figure 14), 
Uba1 charging with ubiquitin to form the Uba1~ubiquitin thioester adduct in vitro (Figure 
18) and effects on the viability of HEK 293 cells (empty vector-transfected control, Uba1-
overexpressing and ubiquitin-overexpressing; (Figure 20 and 21). All of the compounds 
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tested have molecular weights (170.120–458.375) and predicted logP values (0.72–5.95, 
The Lipophilicity plays a significant role in drug discovery and compound design. The 
lipophilicity of an organic compound can be described by a partition coefficient, logP, 
which can be defined as the ratio of the concentration of the unionized compound at an 
equilibrium between organic and aqueous phases. The logP values were calculated with 
the Consensus model implemented in ChemAxon MarvinSketch 19.2) that suggests no 
likely questions of low cell permeability. The combined SAR results from Figures 13, 18, 
20 and 21 are summarized with structures in Figure 23, with calculated IC50 values for 
inhibition in the different assays presented in Supplementary Table 2. EGCG was 
inhibitory in all the assays. The other catechin galloyl ester tested, (−)-epicatechin-3-
gallate (ECG), was also active in all the assays (Figures 13, 18 and 20) and its inhibitory 
effect on cell viability was mitigated with the overexpression of Uba1 or ubiquitin, as 
with EGCG (Figure 21). Of the unesterified catechins tested, (−)-epigallocatechin (EGC) 
displayed weak activity in the PCNA ubiquitination (Figure 14) and Uba1~ubiquitin 
thioester formation assays (Figure 18) while (−)-epicatechin (EC) and (+)-catechin (Cat) 
were inactive in both of these assays (Figures 13 and 18). Unlike EC and Cat, EGC also 
has measurable cytostatic/cytotoxic activity (Figure 20). However, EGC’s negative effect 
on cell survival was not affected by Uba1 or ubiquitin overexpression (Figure 21). Free 
gallic acid (GA) and n-propyl gallate (PG), a short straight-chain alkyl galloyl ester, were 
inactive in the PCNA ubiquitination (Figure 14) and Uba1~ubiquitin thioester formation 
assays (Figure 18) but had little effects on cell viability (Figure 20). What inhibitory 
activity was observed was not mitigated with Uba1 or ubiquitin overexpression (Figure 
21). Longer linear alkyl galloyl esters—n-octyl gallate (OG) and n-dodecyl (lauryl) 
gallate (DG)—were active in all the assays (Figures 13, 18 and 20) and overexpression of 
Uba1 or ubiquitin protected cells from their negative effects on cell survival (Figure 21). 
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Myricetin (Myr) and (+)-dihydromyricetin (DM; also known as ampelopsin) were active 
against PCNA ubiquitination (Figure 14) and Uba1~ubiquitin thioester formation (Figure 
18) but only had very weak activity against cell survival (Figure 20), although cells were 
protected from even that weak cytostatic/cytotoxic activity by overexpression of Uba1 or 
ubiquitin (Figure 21). The alkyl gallates inhibited PCNA ubiquitination and 
Uba1~ubiquitin thioester formation with a potency directly proportional to the length of 
their alkyl chains in the rank order: DG > OG ≫ PG (the last one more-or-less inactive); 
Myr and DM also inhibited PCNA ubiquitination and Uba1~ubiquitin thioester formation 
in the order: Myr ≫ DM (Figures 13, 18, 20 and Supplementary Table 2). However, with 
Myr, unlike with EGCG, pre-incubation of not only Uba1 alone but also ubiquitin alone 
prior to adding the other reaction components for thioester formation resulted in inhibition 
(Figure 15). Since the presence of a Michael acceptor functionality in Myr makes a 
mechanism involving a covalent reaction with the target, which often but not always is 
irreversible, we tested whether Myr irreversibly inhibits PCNA ubiquitination or not by 
determining if enzyme activity recovers after washing out of the compound through serial 
centrifugal filtration. Myr’s inhibitory effects on PCNA ubiquitination, like EGCG’s, 
were reversible (Figure 16). 
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Figure 23. Structure-activity relationships for inhibition of PCNA ubiquitination, 
Uba1~ubiquitin thioester formation and viability of normal, Uba1-overexpressing and 
ubiquitin-overexpressing cells. OE = overexpression, N/A = not applicable.  
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4.13. Robust high-throughput assays to assess discrete steps in PCNA 
ubiquitination  
Starting from the conditions we optimized previously for Western blot analysis and the 
quantitation of PCNA ubiquitination (50 nM Uba1, 50 nM RFC, 50 nM FLAG-PCNA, 
250 nM biotin-ubiquitin, 250 nM Rad6-Rad18, 2 mM ATP and 2.5 nM DNA), we used 
these conditions as a reference for the development of site-specific secondary PCNA 
ubiquitination assay. In the process, we developed a high-throughput Alpha-based PCNA 
ubiquitination assay that balances high sensitivity with low consumption of reagents, as 
well as analogous assays to probe Uba1~ubiquitin thioester formation, Rad6~ubiquitin 
thioester formation, Rad6-Rad18 interaction and Rad18 auto-ubiquitination (Figure 24). 
 
Figure 24. Diagram of the Alpha assays for A. PCNA ubiquitination, B. Uba1~ubiquitin 
thioester formation, C. Rad6~ubiquitin thioester formation and D. Rad18 auto-
ubiquitination.  
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4.13.1. Development of an Alpha assay for Uba1~ubiquitin thioester 
formation 
First, we adapted the Alpha system for the quantitative evaluation of Uba1~ubiquitin 
thioester formation, again starting with the conditions we previously worked out for gel-
based detection (described above) and then refined for Alpha detection. We individually 
varied concentrations of the analytes, FLAG-Uba1 (Figure 25a) and biotin-ubiquitin 
(Figure 25b) and we found conditions yielding good results which 50 nM FLAG-Uba1 
and 150 nM biotin-ubiquitin 
          
Figure 25. Alpha assay for Uba1~ubiquitin thioester formation. a. Variable 
concentrations of FLAG-Uba1 and b. biotin-ubiquitin (Bio-Ub) in the Uba1~ubiquitin 
thioester formation assay 
4.13.2. Development of an Alpha assay for Rad6~ubiquitin thioester 
formation 
We developed an Alpha assay for the detection of Rad6~ubiquitin thioester formation, 
again starting from conditions previously developed for gel-based detection. We 
generated a FLAG-Rad6 construct and performed reactions with non-FLAG-tagged Uba1 
and biotin-ubiquitin. We individually varied concentrations of biotin-ubiquitin (Figure 
26a) and FLAG-Rad6 (Figure 26b) in single-well, "one-pot" reactions which resulted in 
satisfactory results. Thus, we chose 150 nM biotin-ubiquitin and 50 nM FLAG-Rad6 for 
further optimization. We then split the two-reaction sequence into two steps to allow for 
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more narrow screening for direct Rad6 modulators as distinct from those that secondarily 
affect Rad6 by instead directly targeting Uba1, with a first step for Uba1 charging with 
ubiquitin and then a second step where the precharged Uba1~ubiquitin was combined 
with Rad6 (preincubated with compound in a screening setting) for the 
transthioesterification reaction. We found comparably good results to the one-pot reaction 
sequence. 
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Figure 26. Alpha assay for Rad6~ubiquitin thioester formation assay. Titration of 
FLAG-Rad6 and biotin-ubiquitin in the a. FLAG-Rad6 and b. biotin-ubiquitin (Bio-Ub) 
in the Rad6~ubiquitin thioester formation assay. 
 
We experimented with adding EDTA to the precharged Uba1~ubiquitin samples before 
adding Rad6 to chelate the Mg2+ and prevent further ATP-dependent charging of Uba1 
with ubiquitin after mixed with Rad6, so that the assay would be a potentially cleaner 
transthioesterification (despite being a step not requiring Mg2+-ATP) to evaluate 
Rad6~ubiquitin thioester formation solely. However, we found that adding EDTA at this 
step, for some reason, decreased transfer of the ubiquitin moiety from Uba1 to Rad6 
(Figure 27). Another possibility to prevent further Uba1 charging would be to add apyrase 
to cleave ATP between the steps, however, since the assay worked clean enough in the 
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simpler form, we concluded that the addition of another protein component in a screening 
setting may not be warranted. 
 
4.13.3. Development of a Rad6-Rad18 interaction assay 
We developed an Alpha assay for the detection of Rad6-Rad18 interaction. We performed 
reactions with FLAG-tagged Rad6 and His-tagged Rad18. The concentrations of FLAG-
Rad6 and 6xHis-Rad18 were kept in equal ratio and tested in a gradient from 6.25 nM to 
200 nM and again we found conditions that resulted in good outcomes which is 100 nM 
of each FLAG-Rad6 and His-Rad18 (see in figure 28). 
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Figure 28. Alpha assay for Rad6-Rad18 interaction. The equimolar concentrations of 
FLAG-Rad6 and His-Rad18 were tested by going higher in 2x increments from 6.25 nM 
up to 200 nM. 
 
 
Figure 27. Two-step Rad6~ubiquitin thioester 
formation assay, with precharging of Uba1 with 
biotin-ubiquitin prior to addition of Rad6, with or 
without EDTA (added between steps to chelate 
Mg2+ and prevent further ATP-dependent Uba1 
charging with ubiquitin); negative control was 
without ATP, while the positive control and 
EDTA-treated samples included ATP. 
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4.13.4. Development of a Rad18 autoubiquitination assay 
We developed an Alpha assay for the detection of Rad18 autoubiquitination. We 
constructed a FLAG-Rad18 construct and performed reactions with non-FLAG-tagged 
Uba1, non-FLAG-tagged Rad6 and biotin-ubiquitin. Concentrations of FLAG-Rad18 
(Figure 29a) and biotin-ubiquitin (Figure 29b) for this reaction were also varied and again 
the conditions that resulted in good outcomes. The final conditions based on titration 
results we chose 100 nM FLAG-18 and 100 nM biotin-ubiquitin.  
 
Figure 29. Titration of FLAG-Rad18 and biotin-ubiquitin in the Rad18 auto-
ubiquitination assay. a. FLAG-Rad18 and b. biotin-ubiquitin (Bio-Ub)   
59 
 
4.14. Validation of the assays 
In addition to evaluating plate quality control metrics by multiple measures (including Z' 
factors and SSMD values in standard/robust statistical forms to compare positive and 
negative control values, as well as signal-to-background ratios, signal-to-noise ratios and 
signal window values), we further validated the first three Alpha assays with inhibitors of 
ubiquitination we discovered through gel based approach (Fenteany et al. 2020). We 
performed dose-response experiments with the Alpha assays for PCNA ubiquitination 
(Figure 30) and Uba1~ubiquitin thioester formation (Figure 31). The structure-activity 
relationships were similar to those described in Figure 14, 18, 20, 21 and 23, with 
comparable calculated half-maximal inhibitory concentration (IC50) values for each of the 
bioactive compounds, as also shown in Supplementary Table 3. Furthermore, our ongoing 
screening efforts suggest that all of the assays yield predictive results, confirmable by 
other lower-throughput, more traditional assays, in terms of reliable normalized 
percentages of difference from controls and hit selection criteria (z scores and hit-
selection SSMD values) relative to overall experimental means or medians in both 
standard and robust statistical forms, respectively.  
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Figure 30. Dose-response for EGCG and analogs in the PCNA ubiquitination assay. 
Samples were pre-incubated with compounds for 15 min before initiation of the reactions 
with ATP. Data represent mean and SD for 3–7 samples in each case. The final DMSO 
concentration was 1% in all cases. a Dose-response for bioactive inhibitors of PCNA 
ubiquitination, plotted both linearly and semi-logarithmically (inset). b Effect of 
compounds with little activity against PCNA ubiquitination at 500 µM, normalized to 
positive (DMSO alone) control values.   
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Figure 31. Dose-response for EGCG and analogs in the Uba1~ubiquitin formation assay. 
Data represent mean and SD for 3–5 samples in each case. The final DMSO concentration 
was 1% in all cases. FLAG-Uba1 samples were pre-incubated with compounds for 15 
min before addition of biotin-ubiquitin and ATP. a Dose-response for bioactive inhibitors 
of Uba1~ubiquitin thioester formation, plotted both linearly and semi-logarithmically 
(inset). b Effect of compounds with little activity against Uba1~ubiquitin thioester 
formation at 500 µM, normalized to positive (DMSO alone) control values.   
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5. Discussion 
 
We have designed and implemented a powerful quantitative, robust high-throughput 
assay for PCNA ubiquitination, which is a key early event in DNA damage tolerance 
processes. Firstly, we developed alpha assay for PCNA ubiquitination based on pre-
optimized conditions (50 nM Uba1, 50 nM RFC, 50 nM FLAG-PCNA, 250 nM biotin-
ubiquitin, 250 nM Rad6-Rad18, 2 mM ATP and 2.5 nM DNA). We compared the efficacy 
of PCNA ubiquitination as performed through Alpha assay with western blot and found 
the signals to be satisfactory (figure 7). Afterward, we further optimized the reconstituted 
system for a more sensitive Alpha technology. We sought to reduce the concentrations of 
components by the PCNA ubiquitination reaction cascade to further optimize and 
miniaturize the overall subsequent detection step. Thus, we developed a high-throughput 
Alpha-based PCNA ubiquitination assay that balances high sensitivity with low 
consumption of reagents, as well as step-specific assays to probe Uba1~ubiquitin thioester 
formation, Rad6~ubiquitin thioester formation, Rad6-Rad18 interaction and Rad18 
autoubiquitination.  
In the alpha assay, upon high energy illumination with 680 nm wavelength light, the 
phthalocyanine in the donor beads converts ambient oxygen into the excited form. The 
excited singlet oxygen has a half-life of 4 µs and it can travel up to 200 nm distance. In 
case, if the acceptor beads are in the diameter of 200 nm, energy from excited singlet 
oxygen is transferred to thioxene derivatives in acceptor beads subsequently generating 
520-620 nm wavelength light in case of Alphascreen and 615 nm in case of AlphaLISA, 
which are detected by a photomultiplier tube. In case, if there are no acceptor beads in the 
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proximity of donor beads, excited singlet oxygen falls to ground state and no signal is 
produced.  
PerkinElmer's Alpha technology has two variants Alpha Screen and AlphaLISA both are 
similar with a minor difference only in the dyes of acceptor beads. The Alphascreen 
acceptor beads have three dyes, thioxene, anthracene and rubrene while in AlphaLISA 
anthracene and rubrene are substituted with europium chelate. The conversion of thioxene 
to di-ketone derivative by excited singlet oxygen emits 340 nm light which further excites 
europium chelate resulting in narrower wavelength light (615 nm) unlike in Alphascreen. 
We have tested both the subtypes of alpha technology and we don’t see many variations 
in our experimental system. We chose AlphaScreen beads because they are available in a 
kit form (streptavidin donor and anti-FLAG acceptor beads), making it an economical 
option, unlike AlphaLISA.  
The optimized step-specific PCNA ubiquitination assays have good dynamic signal range, 
reproducible, consistent but precise signal intensity values of the range can vary from 
experiment to experiment. Even under identical conditions, alpha counts can display 
different absolute signals, although internally a given experiment will be uniform and 
consistent in trends with others. Perkin Elmer is aware of this issue and technical support 
has no good explanation for it. The important thing is that all experiments are internally 
consistent and after normalization of data, different experiments can be compared. Thus, 
screening data from multiple experiments with replicates should be considered only after 
normalization. Here normalization means, percentage difference from positives in each 
plate.  
The Alpha assay is susceptible to the high-dose hook effect like many other bimolecular 
assays. Wherein, too high concentrations of analytes can result in an absolute drop in 
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signal. The hook effect also referred to as the hooking or prozone effect. It is named after 
the shape of the analyte concentration-signal curve which resembles a fish hook. 
By screening of chemical compounds on our alpha assay for PCNA ubiquitination, we 
discovered EGCG as a potent inhibitor of ubiquitination (Alpha-based PCNA 
ubiquitination assay was the first assay developed in our lab with pre-optimized western 
blot based assay conditions with which we discovered EGCG as a primary hit. Further, 
we pursued it and characterized it through gel-based assay and published our results about 
EGCG and in the background, we worked on further optimization, development of step-
specific secondary assays and validation of IC50 obtained from gel-based assay. EGCG is 
the most active component of green tea. EGCG is known for its anti-angiogenic, anti-
carcinogenic, anti-oxidant, anti-microbial and anti-inflammatory (Chakrawarti et al. 
2016). We found that EGCG abrogates the formation of Uba1~ubiquitin thioester 
conjugate, but not the formation of the Rad6~ubiquitin thioester conjugate resulting from 
the transfer of the ubiquitin moiety from already formed Uba1~ubiquitin. The two most 
common mechanisms to inhibit Uba1~ubiquitin thioester conjugate could be either by 
targeting ubiquitin or Uba1 protein. To investigate this, we carried out preincubation 
experiments where we individually preincubated Uba1 and ubiquitin with EGCG, 
afterward other components were added (Figure15). We found out that the preincubation 
of EGCG with Uba1 protein inhibits the formation of Uba1~ubiquitin thioester conjugate 
not with ubiquitin. This implies that ATP and/or ubiquitin compete effectively with 
EGCG for binding to Uba1 and so EGCG may bind the ATP- or ubiquitin-binding site of 
Uba1. Further, we determined that EGCG binds Uba1 by ligand-detected 1H NMR 
methods with an approximated Kd in a range similar to the IC50 values for inhibition of 
PCNA ubiquitination and Uba1~ubiquitin thioester formation by EGCG, strongly 
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suggesting that it is the direct binding of Uba1 that accounts for the overall inhibitory 
activity. 
EGCG inhibits the autoubiquitination of the E3 ubiquitin ligase TRAF6 (J. Zhang et al. 
2016; A. K. Singh et al. 2016). The reduced TRAF6 ubiquitination could be the result of 
upstream inhibition of Uba1 and not necessarily TRAF6 directly. TRAF6, like Rad18, 
contains a so-called really interesting new gene (RING) zinc finger domain, thought to be 
involved in protein-protein interactions. We have no evidence so far that EGCG directly 
inhibits Rad18 instead our results suggest that EGCG inhibits ubiquitination at the level 
of Uba1. Uba1 has been proposed as a target for the treatment of cancers and other 
pathological states linked to detrimental levels of ubiquitin-proteasome activity and other 
ubiquitination-dependent activities (Xu et al. 2013; Groen and Gillingwater 2015). 
The diverse role of ubiquitination in regulating protein homeostasis and ubiquitin 
signaling indicates the possibility of targeting the ubiquitination pathway to modulate 
human disease. The ubiquitin-proteasome pathway has been mostly validated by the 
success of the proteasome inhibitor bortezomib (Einsele 2014) in the treatment of multiple 
myeloma. However, investigations to validate Uba1 itself as a drug target are still few.  
The first Uba1 inhibitor panepophenanthrin was discovered from the mushroom strain 
Panus rudis Fr. IFO8994 (Sekizawa et al. 2002). It weakly inhibited the Uba1~ubiquitin 
thioester formation in vitro with an IC50 of 72 µM, the activity in cells was not detected. 
After that there have been other  Uba1 inhibitors reported such as himeic acid which 
inhibits with 60-100 µM range (Tsukamoto et al. 2005). Other Uba1 reported are NSC 
622406, largazole that inhibits Uba1~ubiquitin thioester at the adenylation step and small 
molecule hyrtioreticulins A–E inhibitors  (J. Hong and Luesch 2012; Ungermannova et 
al. 2013; 2012; Yamanokuchi et al. 2012). 
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Further, other strong inhibitors such as pyrazolidines PYR-4150 and PYZD-440951 and 
the adenosine sulfamate TAK-243 (formerly known as MLN7243) (Hyer et al. 2018; Y. 
Yang et al. 2007) have been found to target Uba1. TAK-243 is a potent mechanism-based 
inhibitor of the charging of Uba1 with ubiquitin that acts by forming a stable covalent 
adduct with the C-terminal carboxylate of ubiquitin. TAK-243 and related reactive 
adenosine derivatives also likewise indirectly inhibit the E1 enzymes of other ubiquitin-
like proteins to varying degrees (Hyer et al. 2018; Soucy et al. 2009; An and Statsyuk 
2013). In contrast, although considerably less potent than TAK-243, EGCG, myricetin 
and the PYR-41 appears to directly inactivate Uba1 itself rather than ubiquitin (Y. Yang 
et al. 2007). TAK-243 and PYR-41 also differ in some of their biological effects (Monda 
and Cheeseman 2018).  
Besides, Uba1 being the EGCG target relevant to ubiquitination cascade, Uba1 may 
account for part of EGCG’s overall cellular effects. We found that overexpression of Uba1 
in cells reduces the EGCG’s cytostatic and cytotoxic effects, consistent with Uba1 being 
a major intracellular EGCG-binding protein in the cell. This is most likely the result of 
titration of free EGCG by higher Uba1 concentrations in the cell with overexpression. We 
also observed such protective effects with overexpression of ubiquitin, further suggesting 
that the ubiquitination pathway is being targeted in the cell and this is still consistent with 
the hypothesis that Uba1 is the direct target of EGCG relevant to ubiquitination. The 
productive reaction of the Uba1~ubiquitin thioester conjugate is trimolecular (involving 
Uba1 as a covalent catalyst and ubiquitin and ATP as substrates) and overexpression of a 
binding partner of the direct target could be protective if EGCG binds the target 
competitively with that additional component. The protective effects of Uba1 or ubiquitin 
overexpression are specific for EGCG and its biochemically active analogs since neither 
manipulation affects the sensitivity of cells to inactive analogs or puromycin, a well-
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characterized protein synthesis inhibitor employed in our experiments as a representative 
unrelated cytotoxic agent.  
Furthermore, we found that EGCG inhibited global ubiquitination in cells. Previously, 
EGCG treatment has shown upregulation of the expression of the E3 ligase RNF216 and 
thus increases ubiquitination and degradation of one of its substrates, the Toll-like 
receptor 4 (Kumazoe et al. 2017). However, this work was conducted in macrophages at 
a relatively low concentration of EGCG with long treatment duration, conditions that may 
preclude inhibition of Uba1 in the cells (particularly since, with a single treatment over 
longer time scales, EGCG would become extensively degraded and metabolized to 
simpler products), but which results in increased expression of RNF216 and so enhanced 
ubiquitination of its specific substrates.  
While inhibition of Uba1 and ubiquitination may account for part of EGCG’s overall 
activity in cells but EGCG inhibits various other cellular pathways as well. The 
pleiotropic activity profiles are not uncommon for bioactive small molecules and often it 
is indeed the felicitous combination of multiple targets inhibited that is the basis of 
preventive or therapeutic efficacy of a drug.  
The “co-evolution” of natural products with proteins means that they intrinsically have 
favorable protein-binding properties. It can also present challenges in terms of selectivity 
between targets, as many bind conserved motifs in proteins. However, the generation of 
structures derived from or inspired by specific natural products, synthetically or semi-
synthetically, could improve selectivity for one protein over another. Such efforts could 
be guided by comparative SAR studies across different systems.  
We tested EGCG and its analogs which are differing in constitution and stereochemistry 
and an informative multi-assay SAR picture has emerged (summarized with structures in 
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Figure 23). The EGCG-related molecules showed a divergence of diferent SAR profiles, 
with the comparative activity patterns falling into the following four groupings: (1) 
catechin gallates (EGCG and ECG), which show very good correspondence between 
activity profiles in different assays, being inhibitory in the in vitro biochemical (PCNA 
ubiquitination and Uba1~ubiquitin thioester formation) and cellular assays (cell 
viability—with negative effects mitigated by overexpression of Uba1 or ubiquitin); (2) 
simple unesterifed catechins, which display no (EC and Cat) or weak (EGC) activity in 
the assays; (3) longer-chain alkyl gallates (OG and DG), which are active in all the assays, 
with their cytotoxic effects being mitigated in cells by overexpression of Uba1 or 
ubiquitin (while both the short-chain alkyl gallate PG and free GA itself are inactive in 
the biochemical assays and their negative efects on cell viability are unafected by Uba1 
or ubiquitin overexpression); or (4) Myr and DM, which have potent (Myr) or weak (DM) 
activity in the biochemical assays and only weak activity against cell survival, with Uba1 
or ubiquitin overexpression reducing the sensitivity of cells to these compounds.  
All the compounds that exhibited activity in the in vitro PCNA ubiquitination and 
Uba1~ubiquitin thioester formation experiments also had cytostatic/cytotoxic effects that 
were mitigated with the overexpression of Uba1, ubiquitin, or both. This suggests that all 
the bioactive compounds were also binding Uba1 and/or ubiquitin in the cell and that 
inhibition of ubiquitination at that level is relevant to the physiological activity of all these 
compounds. However, it is possible and indeed likely that the different structural classes 
of bioactive compounds, while each targeting some site on Uba1 and/or ubiquitin itself 
are also mechanistically distinct.  
The potent inhibitory activity of the catechin gallates against the ubiquitination cascade 
appears to require a composite structure of both catechin and galloyl moieties. EGCG is 
an ester of EGC and GA, while ECG is an ester of EC and GA. Free EGC itself has weak 
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activity in the biochemical assays, while free GA is inactive, as is free EC. It is known 
that galloylation also strongly influences various other bioactivities of catechins and other 
natural products (Karas, Ulrichová, and Valentová 2017). Furthermore, the 5′-OH of the 
B ring on the catechin skeleton of EGCG seems to play a role in the activity, possibly 
through hydrogen bonding with Uba1, since ECG, which lacks this hydroxyl group, has 
slightly diminished biochemical activity. Similarly, free EGC by itself still possesses 
some activity, while EC does not, again demonstrating the significance of the B-ring 5′-
OH.  
The mechanism of action of the longer-chain alkyl gallates (OG and DG) in inhibiting 
ubiquitination may be distinct from that of the catechin gallates and Myr (and its formal 
hydrogenation product DM). OG and DG, both esters of n-alkanols (of length C8 and 
C12, respectively) and GA, are amphiphiles with a polar “head” and straight-chain 
hydrophobic “tail.” They may have detergent-like local-denaturing effects upon binding, 
consistent with the increasing inhibitory activity in the biochemical assays with longer 
alkyl chain, with the order of potency being DG > OG ≫ PG. They exhibit high inherent 
variability in the biochemical experiments and DG, in particular, displays large 
divergence in potency between the PCNA ubiquitination and Uba1~ubiquitin thioester 
formation assays (Supplementary Table 2). These results suggest that, unlike the catechin 
gallates and Myr, the alkyl gallates may weakly inhibit multiple components of the 
cascade in the PCNA ubiquitination assay and without a single specific recognition 
interaction, with less of the more straightforward drug-like behavior against Uba1 
exhibited by the other bioactive compound classes.  
Myr likely also has a unique mechanism of action. Myr and DM are both ketone carbonyl 
compounds and they do not have galloyl moiety, this may be key to their activity different 
from catechin gallates. Myr potently inhibits thioester formation whether pre-incubated 
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with Uba1 alone or ubiquitin alone before the addition of other reaction components, 
unlike EGCG. These results suggest either that Myr binds Uba1 non-competitively with 
ATP and ubiquitin or that Myr binds ubiquitin directly, in either case inhibiting the 
formation of the Uba1~ubiquitin thioester by a mechanism that is distinct from EGCG. 
Myr and DM are both ketone carbonyl compounds and this may be key to their activity.  
The strong activity of Myr may be tied to its Michael acceptor (α,β-unsaturated carbonyl) 
functionality, a potentially reactive electrophile (β carbon of the α,β-unsaturated carbonyl 
in Myr, Figure 23) susceptible to attack by nucleophile on Uba1(such as the side-chain 
thiol of its active-site cysteine, normally involved in the reaction with ubiquitin to form 
the Uba1~ubiquitin thioester adduct).  In DM, which lacks an α,β-unsaturated carbonyl, 
is much more weakly active for ubiquitination and Uba1~ubiquitin thioester formation 
than Myr, consistent with such a mechanism.  
The Michael reaction is often irreversible, we tested whether Myr irreversibly inhibits 
Uba1 and/or ubiquitin function or not. We found that Myr, like EGCG, appears to inhibit 
ubiquitination reversibly. A covalent though the reversible reaction is still not unlikely to 
be involved. The electronic and steric effects of the substitution pattern on the α and β 
carbons, as well as the nature of the incoming nucleophile on the target, may make 
Michael addition to Myr reversible through β elimination. Indeed, such chemical 
parameters are known to influence reactivity and reversibility in Michael acceptors, with 
numerous examples of reversible bioactive Michael acceptor-containing compounds in 
the literature (H. Johansson 2012; Jackson et al. 2017).  
The Michael reaction is a 1,4-addition (conjugate addition) reaction, another reaction 
typical of these systems is 1,2-addition (direct addition), where the nucleophile reacts with 
the carbonyl carbon instead of the β carbon. The direct addition is kinetically favored, 
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though not thermodynamically over conjugate addition. It is generally reversible for 
weakly basic nucleophiles, such as thiols, alcohols and amines, the most common 
nucleophiles present in proteins. Therefore, a reversible covalent protein-small molecule 
species could also be the result of the direct addition of a protein nucleophile to the ketone 
carbonyl on Myr, a reaction also available to DM. Both reversible Michael addition and 
direct addition are possibilities to explain why the α,β-unsaturated carbonyl appears 
important for activity in Myr and these candidate mechanisms are not mutually exclusive. 
In contrast, in DM, only a direct addition to the ketone is possible, which could 
conceivably explain its weak residual activity. This is consistent with the observation that 
Cat, which differs from DM only in lacking the ketone, is entirely inactive. Thus, both 
conjugate and direct addition may be involved in Myr’s inhibitory activity, with conjugate 
addition likely playing the larger role.  
However, it is also important to consider the structural explanations that do not involve 
any covalent reaction. The compounds differ geometrically besides electronically. Myr 
possesses a planar α, β-unsaturated system, while DM has tetrahedral α and β centers. 
Therefore, Myr’s mechanism of action could involve reversible covalent reaction(s), non-
covalent inhibitory interaction between small molecule and protein, or a combination of 
these non-mutually exclusive mechanisms. 
After SAR studies, we further validated the assays with EGCG and its analogs in our 
Alpha based site-specific PCNA ubiquitination assays (Figure 31 and 31). We performed 
dose-response experiments with the Alpha assays for PCNA ubiquitination and 
Uba1~ubiquitin thioester formation. The structure-activity relationships discussed above 
were similar trends in relative calculated IC50 values for each of the bioactive compounds. 
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Green tea polyphenols, particularly EGCG, have widely acknowledged potential as 
preventive or therapeutic agents against a range of cancers and other disease states. 
Inhibition of Uba1 and ubiquitination, recognized as promising loci for therapeutic 
intervention in many of the same diseases, may account for part of EGCG’s overall 
biological effects and so the present work may help lead to a better understanding of 
EGCG’s health-beneficial properties. Moreover, the fact that EGCG and its analogs fall 
into distinct mechanistic subclasses that are rather cleanly correlated to structure opens 
up exciting possibilities for future research. Each series of the bioactive small molecule 
identified represents a different first-in-class type of chemical modulator of 
ubiquitination, a hierarchical cascade of reactions that has drawn great interest from both 
the basic research and drug discovery communities. In the future, improved specificity 
and selectivity may arise from the assessment of further natural, semisynthetic, or 
synthetic congeners of the pharmacophore types delineated in the present study, yielding 
valuable therapeutic drug leads and tools from these different structural and mechanistic 
sets of molecules.  
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8. Summary 
 
The DNA is continuously exposed at different stages of the cell cycle to various factors 
that work as a DNA damage agent and causes DNA damage. There are endogenous as 
well as exogenous factors such as reactive oxygen species, UV radiations, nitrogen 
mustard, formaldehyde, etc. that insults the DNA in various forms. The DNA damage 
triggers specialized DNA damage repair mechanisms. In some cases, classical DNA 
repair mechanisms are unable to repair the lesion and if the DNA damage left unrepaired, 
it stalls the progressing replication fork in S-phase of the cell cycle. At stalled replication 
fork, PCNA undergoes monoubiquitination at K164 residues with the help of ubiquitin-
activating enzyme UBA1 (E1), ubiquitin-conjugating enzyme Rad6 (E2) and Ubiquitin 
ligase Rad18 (E3). The monoubiquitination of PCNA works as a molecular switch that 
recruits special class of polymerases so-called translesion synthesis (TLS) polymerases. 
TLS polymerases carry out likely error-prone replication, which can lead to mutagenesis 
and carcinogenesis. This kind of repair, which is error-prone and involves TLS 
polymerases, known as Translesion DNA synthesis.  
We have developed a high throughput assay to screen for modulators of PCNA 
ubiquitination a key step involved in TLS synthesis, error-prone DNA damage repair 
pathway. We further refined the reconstituted systems for the more sensitive Alpha 
technology. We sought to reduce the concentrations of the components in the reactions 
and optimize the subsequent detection step of the assays like Uba1~ubiquitin thioester, 
Rad6~ubiquitin thioester, Rad6-Rad18 interaction assay and Rad18 auto-ubiquitination 
assay.  
We have discovered a green tea molecule EGCG, a potent inhibitor of Uba1~Ubiquitin 
thioester formation thus inhibiting ubiquitination. We have tested EGCG in HEK 293 cell 
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and we have observed it has anti-proliferative activity. NMR studies have also shown 
which proves the direct binding of EGCG with Uba1. The EGCG and Uba1 interactions 
are reversible which has been studied by carrying out centrifugal washout experiments. 
Overexpression of Uba1 in HEK 293 cells protects them from inhibitory effects of EGCG. 
Furthermore, we have found out that EGCG inhibits global ubiquitination in cells.   
EGCG and related molecules have been tested for PCNA ubiquitination, Uba1~ubiquitin 
thioester, effects on the viability of HEK 293 cells. The catechin galloyl ester EGCG and 
ECG tested were active in all the assays. The unesterified catechins tested, (−)-
epigallocatechin (EGC) displayed weak activity in the PCNA ubiquitination and 
Uba1~ubiquitin thioester formation assays, while (−)-epicatechin (EC) and (+)-catechin 
(Cat) were inactive in both of these assays. Unlike EC and Cat, EGC also has measurable 
cytostatic/cytotoxic activity. However, EGC’s negative effect on cell survival was not 
affected by Uba1 or ubiquitin overexpression. Free gallic acid (GA) and n-propyl gallate 
(PG), a short straight-chain alkyl galloyl ester, were inactive in the PCNA ubiquitination 
and Uba1~ubiquitin thioester formation assays but had little effects on cell viability. The 
inhibitory activity was observed, was not mitigated with Uba1 or ubiquitin 
overexpression. Longer linear alkyl galloyl esters—n-octyl gallate (OG) and n-dodecyl 
(lauryl) gallate (DG)—were active in all the assays and overexpression of Uba1 or 
ubiquitin protected cells from their negative effects on cell survival. Myricetin (Myr) and 
(+)-dihydromyricetin (DM; also known as ampelopsin) were active against PCNA 
ubiquitination and Uba1~ubiquitin thioester formation but only had very weak activity 
against cell survival, although cells were protected from even that weak 
cytostatic/cytotoxic activity by overexpression of Uba1 or ubiquitin. The alkyl gallates 
inhibited PCNA ubiquitination and Uba1~ubiquitin thioester formation with a potency 
directly proportional to the length of their alkyl chains in the rank order: DG > OG ≫ PG 
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(the last one more-or-less inactive); Myr and DM also inhibited PCNA ubiquitination and 
Uba1~ubiquitin thioester formation in the order: Myr ≫ DM. However, with Myr, unlike 
with EGCG, preincubation of not only Uba1 alone but also ubiquitin alone prior to adding 
the other reaction components for thioester formation resulted in inhibition. Since the 
presence of a Michael acceptor functionality in Myr makes a mechanism involving a 
covalent reaction with the target, which often but not always is irreversible, we tested 
whether Myr irreversibly inhibits PCNA ubiquitination or not by determining if enzyme 
activity recovers after washing out of the compound through serial centrifugal filtration. 
Myr’s inhibitory effects on PCNA ubiquitination, like EGCG’s, were reversible. We 
found half-maximal inhibitory concentration (IC50) values and structure-activity 
relationship trends for Uba1 inhibitors we previously reported as determined by the Alpha 
assay generally corresponding to other more traditional methods in terms of both 
inhibitions the overall PCNA ubiquitination cascade and Uba1 specifically. Thus, the 
system works not only as a screening tool for this reaction sequence but also as a 
legitimate quantitative method for measuring ubiquitination and formation of thioester 
conjugates without further modification from its high-throughput format.  
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9. Összefoglaló 
A DNS a sejtciklus során folyamatosan károsító tényezőknek van kitéve. Ezek között a 
tényezők között találunk exogén és endogén ágenseket, mint például reaktív oxigén 
gyökök, UV sugárzás, nitrogén-mustár, formaldehid, stb., amelyek különféle módon 
rongálják a DNS-t. A DNS-károsodások a sejtekben olyan különböző mechanizmusokat 
aktiválnak,  melyeknek az a szerepe, hogy kijavítsák a keletkezett hibákat, ezért ezeket 
együttesen DNS-hibajavító mechanizmusoknak nevezzük. Jelen dolgozatban elsősorban 
a posztreplikációs hibajavító mechanizmussal foglalkozunk, amelyik az elakadt 
replikációs villánál indul. Ennek első fázisában a PCNA poszttranszlációs módosításon 
esik át, ami lehet ubikvitinálás vagy SUMOiláció, melyek révén egyrészt egyéb fehérjéket 
aktivál, másrészt meghatározza, hogy mely útvonalon haladjon a DNS-hibajavítás 
mechanizmusa. A PCNA molekula az elakadt replikációs villánál az UBA1 ubikvitin-
aktiváló enzim, a Rad6 ubikvitin-konjugáz és a Rad18 ubikvitin-ligáz hatására a K164-es 
lizinjén monoubikvitinálódik. A monoubikvitinált PCNA a polimerázok egy speciális 
családját, az ún. TLS (transzléziós szintézis) polimerázokat toborozza a hibához. Ezek a 
polimerázok hibásan írják át a DNS-szálat, ami mutagenezishez és végső soron 
karcinogenezishez vezet. Azt a folyamatot, amely hibás DNS-átírást eredményez és a TLS 
polimerázok révén valósul meg, transzléziós DNS szintézisnek nevezzük.  
Munkám során egy nagy áteresztőképességű szűrő módszert fejlesztettem ki, amely képes 
azonosítani a PCNA ubikvitinálást befolyásoló molekulákat. Ezt követően tovább 
fejlesztettük a felállított rendszert a jóval érzékenyebb Alpha technológiához. Célunk a 
reakciókban használt komponensek koncentrációjának csökkentése és az azt követő 
kimutatási lépés optimalizálása volt, az Uba1-ubikvitin tioészter, a Rad6-ubikvitin 
tioészter, a Rad6-Rad18 interakciós, valamint a Rad18 autoubikvitilálási assay-k esetén.  
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A tesztek során sikeresen azonosítottunk egy a zöld teában lévő vegyületet, az EGCG-t 
(epigallocatechin gallát), amely az Uba1-ubikvitin tioészter komplex kialakulásának 
potenciális inhibitora, és ezáltal a PCNA ubikvitinálás hatékony gátlója lehet. Ezt 
követően az EGCG molekulát in vitro teszteltük HEK293 sejtvonalban, ahol 
sejtosztódásgátló hatást mutatott. A sejtmagi mágneses rezonancia (NMR) tesztek 
igazolták az EGCG és az Uba1 közvetlen kapcsolódását. Az EGCG és az Uba1 közötti 
kölcsönhatás reverzibilis, amit centrifugális-kimosási kísérletekkel vizsgáltunk. Az Uba1 
fehérje HEK293 sejtekben történő túltermeltetése védelmet nyújtott az EGCG gátló 
hatásával szemben. Továbbá kimutattuk, hogy az EGCG globálisan gátolja az 
ubikvitinálást a sejtekben.  
Vizsgáltuk az EGCG és rokon molekuláinak hatását a PCNA ubikvitinálásra, az Uba1-
ubikvitin tioészter komplexre és a HEK293 sejtek túlélésére. A kísérletekhez használt 
catechin galloyl észter EGCG és ECG (epigallocatechin) a tesztek során végig aktívnak 
mutatkozott. A nem-észterezett cathechin és (−)-ECG csupán alacsony aktivitást mutatott 
úgy a PCNA ubikvitinálás, mint az Uba1-ubikvitin tioészter formálás alkalmával, míg az 
(−)-epicatechin (EC) és a (+)-catechin (Cat) mindkét esetben inaktív maradt. Az EC-vel 
és a Cat-tal ellentétben az ECG-nek mérhető citosztatikus/citotoxikus hatása is volt. Az 
ECG negatív hatását a sejtek túlélésére nem befolyásolta az Uba1 vagy az ubikvitin 
túltermeltetése. A szabad galluszsav (GA) és az n-propyl gallát (PG), egy rövid, egyenes 
láncú alkil-galloil-észter, szintén inaktív volt a PCNA ubikvitinálás és az Uba1-ubikvitin 
tioészter komplex formációs tesztek során, de a sejtek túlélését kis mértékben 
befolyásolták.  Ezt a gátló hatást az Uba1 vagy az ubiquitin túlzott expressziója nem 
mérsékelte. A hosszabb egyenes láncú alkil galloil észterek, az n-octil gallát (OG) és az 
n-dodecil (lauril) gallát (DG), minden vizsgált tesztben aktívak voltak, és az Uba1 vagy 
az ubikvitin túltermelése védelmet nyújtott a sejteknek a túlélésre gyakorolt negatív 
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hatástól. A miricetin (Myr) és a (+)-dihidromiricetin (DM; vagy ampelopsin) a PCNA 
ubikvitinálás és Uba1-ubikvitin tioészter komplex formációs tesztek során aktivitást 
mutattak, de a sejtek túlélésére csak gyenge hatást gyakoroltak, az Uba1 vagy az ubikvitin 
túltermelése pedig ezzel a gyenge citosztatikus/citotoxikus hatással szemben is védelmet 
biztosított. Az alkil-gallátok a bennük található alkil lánc hosszával arányos mértékben 
gátolták a PCNA ubikvitinálást és az Uba1-ubikvitin tioészter komplex képződést a 
következők szerint: DG > OG ≫ PG (utóbbi alig mutatva már mérhető aktivitást). A Myr 
és a DM szintén gátolta a PCNA ubikvitinálást és az Uba1-ubikvitin tioészter komplex 
képződést, ebben a sorrendben: Myr ≫ DM. Míg az EGCG esetében csak az Uba1-gyel 
történő előinkubálás vezetett gátláshoz a tioészter komplex formálódási teszt során, addig 
a Myr esetében ez a gátlás az ubikvitinnel történt előinkubálás esetén is megfigyelhető 
volt. Azt is megvizsgáltuk, hogy a Myr irreverzibilisen gátolja-e a PCNA ubikvitinálást, 
mérve az enzimaktivitás helyreállását azt követően, hogy a ligandumot kimostuk a 
komplexből sorozatos centrifugálásos-szűréses fázisok segítségével. A Myr az EGCG-
hez hasonlóan reverzibilisen gátolja a PCNA ubikvitinálódást, ami azzal magyarázható, 
hogy a Myr-ben található Michael-féle akceptor funkciós csoport nem minden esetben 
eredményez kovalens reakciót a targettel.  
Az Uba1-gátlók esetében tapasztalt fél maximális gátlókoncentráció (IC50) értékek és a 
szerkezet-aktivitás összefüggési tendenciák Alfa-teszttel meghatározva hasonlóak, mint 
amelyeket korábban közöltünk hagyományosabb módszerrel, az általános PCNA 
ubikvitinálási kaszkádban és az Uba1 által érintett folyamatban egyaránt. Így a rendszer 
nemcsak ennek a kölcsönhatásnak a szűrőeszközeként működik, hanem legitim 
kvantitatív módszerként széleskörűen is alkalmazható az ubikvitináció és a tioészter-
konjugátumok képződésének mérésére, anélkül, hogy tovább kellene módosítani nagy 
áteresztőképességű jellegét.  
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11. Appendix 
 
 
 
 
Figure S1. PCNA ubiquitination reaction volumes. The reaction with optimized 
conditions was performed in reaction volumes of 5 µl, 10 µl and 20 µl, with incubation 
for 2 h at 25 °C, followed by Alpha detection with the assay carried out otherwise as 
described in the Materials and Methods section. Figure S2. Donor and acceptor bead 
incubation times for the detection of ubiquitinated PCNA. Times of incubation with beads 
before Alpha detection were evaluated with donor and acceptor bead concentrations at 
10 μg/ml each. Data represent mean and SD for 3 samples. Figure S3. Dilution factors 
for the detection of ubiquitinated PCNA. PCNA ubiquitination reactions were diluted to 
different degrees as indicated in Alpha buffer with donor and acceptor beads, followed by 
incubation and detection. Data represent mean and SD for ≥3 samples. Top and bottom 
panels represent two separate experiments with different ranges of dilution. 
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Figure S4. The donor and acceptor bead concentrations. The concentrations of donor and 
acceptor beads were varied, as indicated, followed by incubation and detection. Data 
represent mean and SD for 4 samples. Figure S5. The donor and acceptor bead ratios 
(values in μg/ml) were varied, followed by incubation and detection. Data represent mean 
and SD for 7–8 samples. D = donor beads; A = acceptor beads. Figure S6. Donor and 
acceptor bead order of addition for detection of ubiquitinated PCNA. The order of 
addition of Alpha donor and acceptor beads was examined, with incubation for 2 h with 
one and then further for 2 h after addition of the other (compared to simultaneous addition 
and incubation for 2 h or 4 h), followed by detection. Data represent mean and SD for 3 
samples. D = donor beads; A = acceptor beads. 
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Figure S7 and S8.  Variation of DMSO tolerance and ATP concentration in Alpha assay 
for PCNA ubiquitination. S7. Different concentrations of DMSO were added to the 
reactions, followed by incubation and detection. Data represent mean and SD for 3 
samples. S8ATP concentrations for the PCNA ubiquitination cascade were varied, 
followed by incubation and detection. Data represent mean and SD for 3 samples.  
Note: The PCNA ubiquitination conditions for Figures S1, S2, S3, S4, S5, S6, S7 and S8 
were based on Figures 8 and 9 in the Results and Conclusion section. 
 
Supplementary Table 1.  
Compounds Company  Catalog no. 
(–)-Epigallocatechin-3-gallate Avicor and Selleck 
Chemicals 
Selleck Chemicals 
Cat#S2250 
(–)-Epicatechin-3-gallate Selleck Chemicals Cat#S3925 
(–)-Epigallocatechin Selleck Chemicals Cat#S3922 
(–)-Epicatechin Selleck Chemicals Cat#S4723  
(+)-Catechin Selleck Chemicals Cat#S4722 
Gallic acid  Selleck Chemicals Cat#S4603 
n-Propyl gallate Avicor N/A 
n-Octyl gallate Avicor N/A 
n-Dodecyl gallate Avicor N/A 
Myricetin Avicor and Adooq 
Bioscience 
Adooq Bioscience 
Cat#A10615 
(+)-Dihydromyricetin Avicor and Adooq 
Bioscience 
Adooq Bioscience 
Cat#A1025 
 
Supplementary Table 2.  
Half-maximal inhibitory concentration (IC50) values for compounds against PCNA 
ubiquitination and Uba1~ubiquitin thioester formation and effects on the viability 
of normal, Uba1-overexpressing and ubiquitin-overexpressing cells. All IC50 values, 
standard errors and 95% confidence intervals listed were calculated by nonlinear 
regression with GraphPad Prism software. The effects of compounds on cell survival in 
Uba1 and ubiquitin-overexpressing cells relative to empty vector-transfected control cells 
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are also shown. SE = standard error; CI = 95% confidence interval; n = number of 
independent experiments; N/A = not applicable. 
 
Compoun
d 
IC50 for 
inhibition of 
PCNA 
ubiquitinatio
n 
IC50 for 
inhibition of 
Uba1~ubiquiti
n thioester 
formation 
IC50 for 
inhibitio
n of cell 
survival 
Effect of Uba1 
overexpressio
n on cell 
survival 
Effect of 
ubiquitin 
overexpressio
n on cell 
survival 
EGCG 0.2280 µM 
(SE = 
0.03419; CI: 
0.1714–
0.3192; n = 7) 
1.632 µM (SE = 
0.4580; CI:  
0.8348–3.451; n 
= 4) 
220.2 µM 
(SE = 
18.90; CI: 
187.4–
263.5; n = 
6) 
Protects Protects 
ECG 0.5369 µM 
(SE = 
0.09460; CI: 
0.3750–
0.8431; n = 4) 
4.223 µM (SE = 
2.161; CI: 
1.263–13.77; n 
= 6) 
261.7 µM 
(SE = 
33.88; CI: 
206.2–
353.4; n = 
6) 
Protects Protects 
EGC 43.28 µM (SE 
= 22.81; CI: 
16.08–129.0; 
n = 4) 
7.584 µM (SE = 
3.869; CI: 
2.927–20.67; n 
= 7) 
175.7 µM 
(SE = 
18.05; CI: 
144.0–
218.5; n = 
4) 
Does not 
protect 
Does not 
protect 
EC > 500 µM (n = 
3) 
> 500 µM (n = 
4) 
> 500 µM 
(n = 4) 
N/A N/A 
Cat > 500 µM (n = 
3) 
> 500 µM (n = 
4) 
> 500 µM 
(n = 4) 
N/A N/A 
GA > 500 µM (n = 
3) 
> 500 µM (n = 
4) 
240.7 µM 
(SE = 
18.12; CI: 
206.6–
280.3: n = 
4) 
Does not 
protect 
Does not 
protect 
PG > 500 µM (n = 
3) 
> 500 µM (n = 
4) 
176.3 µM 
(SE = 
23.55; CI: 
135.8–
240.4; n = 
4) 
Does not 
protect 
Does not 
protect 
OG 10.32 µM (SE 
= 6.406; CI: 
3.182–40.09; 
n = 4) 
80.60 µM (SE = 
33.90; CI: 
34.81–405.1; n 
= 4) 
38.70 µM 
(SE = 
3.106; CI: 
Protects Protects 
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32.72–
45.46; 
n = 4) 
DG 1.633 µM (SE 
= 0.3117; CI: 
1.048–2.670; 
n = 5) 
35.00 µM (SE = 
25.11; CI: 
6.288–533.1; n 
= 4) 
33.46 µM 
(SE = 
3.247; CI: 
27.15–
40.83; n = 
4) 
Does not 
protect 
Protects 
Myr 1.213 µM (SE 
= 0.2083; CI: 
0.8755–4.201; 
n = 5) 
0.7207 µM (SE 
= 0.4970; CI:  
0.1766–2.680; n 
= 5) 
> 500 µM 
(n = 6) 
Protects Protects 
DM 66.43 µM (SE 
= 38.92; CI: 
27.21–180.9; 
n = 3) 
14.27 µM (SE = 
3.140; CI: 
5.927–22.18; n 
= 3) 
> 500 µM 
(n = 6) 
Does not 
protect 
Protects 
 
 
Supplementary Table 3.  
Half-maximal inhibitory concentration (IC50) values for compounds against PCNA 
ubiquitination and Uba1~ubiquitin thioester by Alpha assay compared to other 
methods. All IC50, standard error (SE) and 95% confidence interval (CI) values listed 
were calculated by nonlinear regression with GraphPad Prism 8 software; n = number of 
replicates; Ind. = indeterminate. 
Compound IC50 for 
inhibition of 
PCNA 
ubiquitination 
(Alpha) 
IC50 for 
inhibition of 
PCNA 
ubiquitination 
(Western blot)  
IC50 for 
inhibition of 
Uba1~Ub 
thioester 
formation 
(Alpha) 
IC50 for 
inhibition of 
Uba1~Ub 
thioester 
formation (gel-
based) 
EGCG 0.05656 µM (SE 
= 0.009536; CI: 
0.04086–
0.07757; n = 5) 
0.2280 µM (SE 
= 0.03419; CI: 
0.1714–0.3192; 
n = 7) 
0.4878 µM (SE 
= 0.1446; CI: 
0.2586–
0.9488; n = 3) 
1.632 µM (SE = 
0.4580; CI:  
0.8348–3.451; n 
= 4) 
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ECG 0.09879 µM (SE 
= 0.04420; CI: 
0.03177–0.2749; 
n = 4) 
0.5369 µM (SE 
= 0.09460; CI: 
0.3750–0.8431; 
n = 4) 
0.6706 µM (SE 
= 0.3549; CI: 
Ind.–0.9978; n 
= 3) 
4.223 µM (SE = 
2.161; CI: 1.263–
13.77; n = 6) 
EGC 6.620 µM (SE = 
3.228; CI:  
2.916–16.52; n = 
3) 
43.28 µM (SE 
= 22.81; CI: 
16.08–129.0; n 
= 4) 
5.960 µM (SE 
= 17.28; CI: 
0.1009–Ind.; n 
= 3) 
7.584 µM (SE = 
3.869; CI: 2.927–
20.67; n = 7) 
EC > 500 µM (n = 6) > 500 µM (n = 
3) 
> 500 µM (n = 
3) 
> 500 µM (n = 4) 
Cat ca. 500 µM (n = 
6) 
> 500 µM (n = 
3) 
> 500 µM (n = 
3) 
> 500 µM (n = 4) 
GA > 500 µM (n = 6) > 500 µM (n = 
3) 
ca. 500 µM (n 
= 3) 
> 500 µM (n = 4) 
PG > 500 µM (n = 4) > 500 µM (n = 
3) 
> 500 µM (n = 
3) 
> 500 µM (n = 4) 
OG 3.083 µM (SE = 
0.6111; CI: 
2.589–6.353; n = 
3) 
10.32 µM (SE 
= 6.406; CI: 
3.182–40.09; n 
= 4) 
13.36 µM (SE 
= 6.018; CI: 
5.341–38.48; n 
= 3) 
80.60 µM (SE = 
33.90; CI: 34.81–
405.1; n = 4) 
DG 3.727µM (SE = 
0.5664; CI: 
2.833–4.557; n = 
3) 
1.633 µM (SE 
= 0.3117; CI: 
1.048–2.670; n 
= 5) 
44.42 µM (SE 
= 22.42; CI: 
18.82–149.6; n 
= 3) 
35.00 µM (SE = 
25.11; CI: 6.288–
533.1; n = 4) 
Myr 0.7599 µM (SE = 
0.3928; CI: 
0.3229–2.614; n 
= 3) 
1.213 µM (SE 
= 0.2083; CI: 
0.8755–4.201; 
n = 5) 
1.592 µM (SE 
= 0.7459; CI: 
0.7213–4.216; 
n = 3) 
0.7207 µM (SE = 
0.4970; CI: 
0.1766–2.680; n 
= 5) 
DM 28.68 µM (SE = 
5.299; CI: 19.68–
49.40; n = 4) 
66.43 µM (SE 
= 38.92; CI: 
27.21–180.9; n 
= 3) 
29.62 µM (SE 
= 15.14; CI: 
8.656–125.1; n 
= 4) 
14.27 µM (SE = 
3.140; CI: 5.927–
22.18; n = 3) 
 
 
